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Particulate

hexavalent

chromium

(Cr(VI))

compounds

are

human

lung

carcinogens. However, their carcinogenicity is poorly understood. The best model for
Cr(VI)-induced carcinogenesis involves the acquisition of structural and numerical
chromosome instability (CIN). Many mechanisms contribute to CIN. Among these,
centrosomes play a pivotal role because they dictate proper segregation of
chromosomes during cell division. Cr(VI) causes centrosome amplification, a phenotype
where cells have extra centrosomes and hence can undergo unequal distribution of
chromosomes resulting in CIN. How Cr(VI) induces these abnormalities is unknown.
Moreover, whether Cr(VI)-induced centrosome amplification is a permanent phenotypic
change is also unknown. This work investigates the permanence of the centrosome
amplification phenotype and explores centrosome defects that can lead to centrosome
amplification.
We analyzed centrosome numbers in clonal cell lines developed from repeated
exposures to Cr(VI). We found that these cells lines develop a permanent centrosome
amplification phenotype after one, two or three exposure to Cr(VI). Moreover, permanent

centrosome amplification correlates with the acquisition of permanent changes in
chromosome numbers and hence, numerical CIN.
In addition, we investigated centriole disengagement which is the licensing step
of centrosome duplication. We found that chronic exposure to particulate Cr(VI) induces
premature centriole disengagement in interphase. Consistent with this, we observed a
decrease in securin and increase in active separase and Plk1, which regulate the
disruption of the S-M protein linker that holds centrioles together.
Chronic exposure to Cr(VI) also caused premature centrosome separation in
interphase, suggesting that Cr(VI) has the potential to affect the other centrosome
protein linker (i.e. G1-G2 tether) which holds duplicated centrosomes together. Cr(VI)
also decreases protein levels and localization of Nek2 and Eg5, proteins involved in
centrosome separation.
Overall, the data indicate that Cr(VI) targets many aspects of centrosome
biology. We propose that disruption of the G1-G2 tether leads to premature disruption of
the S-M linker causing centriole disengagement and triggering centrosome duplication.
This causes centrosome amplification, which leads to numerical CIN and ultimately,
neoplastic transformation and cancer.
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CHAPTER 1
INTRODUCTION

1.1. Overview
Hexavalent chromium (Cr(VI) is a metal widely used in the chemical, refractory
and metal industries. It is also a well-established human lung carcinogen. Cr(VI)-induced
tumors are caused by Cr(VI) particles that are deposited in bronchial bifurcations. These
particles dissolve over time and as they do, the chromate anions enter the surrounding
cells. Once inside cells, Cr(VI) is reduced and in the process potent genotoxic
metabolites are formed. DNA damage is a key aspect of Cr(VI) carcinogenicity. Cr(VI)
tumors are characterized by chromosome instability, a phenotype that results in the
development of complex karyotypes with abnormal number of chromosomes as well as
structural damage to chromosomes. Chromosome instability is a major driving force of
Cr(VI) carcinogenicity.
Proper chromosome segregation is key to maintaining normal number and
structurally intact chromosomes. Centrosomes are organelles responsible for forming
the mitotic spindle that segregates chromosomes during cell division. Many solid tumors,
including lung tumors, have extra number of centrosomes that contribute to the
acquisition of a chromosome instability phenotype. Centrosome numbers are tightly
regulated by the centrosome cycle. However chemicals can negatively impact the
centrosome cycle and cause centrosome abnormalities. Metals, including Cr(VI), cause
centrosome amplification in human cells, although the underlying mechanisms are
currently unknown. Here we present an overview of Cr(VI) uses, exposure and
carcinogenicity. We also describe centrosomes and their role in carcinogenesis, as well
as the current state of knowledge on metal-induced centrosome abnormalities.

1

1.2. Chromium
Chromium (Cr) is a naturally occurring metal. It has multiple valence states (-2 to
+6) but the most stable are the elemental [Cr(0)], trivalent [Cr(III)] and hexavalent
[Cr(VI)]. Even though all of these forms are present in nature, Cr(III) is the most stable
and predominant one, mostly found in the mineral chromite [(Fe, Mg)O(Cr, Al, Fe)2O4].
About 95% of the chromite ores are located in southern South Africa, Zimbabwe and
Kazakhstan (USGS, 2012). Cr(VI) in natural form is present in various minerals but in
small amounts, and hence, these minerals are not extracted for commercial purposes.
The majority of Cr(VI) in the environment is man-made and derives from the production
and use of Cr(VI) compounds. Cr(VI) is made by milling and mixing chromite with soda
ash and heating the mixture to oxidize Cr(III) to a soluble form of Cr(VI), which is then
leached out of the mixture (OSHA, 2006).
Cr is lustrous, hard, and brittle, has a high melting point and is very resistant to
corrosion. Cr compounds are also brightly colored in different shades of violets, greens,
yellows, oranges and reds. Because these are highly desirable properties in industry, Cr
is extracted from the mineral chromite to be used in metal, chemical and refractory
industries. Cr has been widely used in industry for over 100 years and for many
applications is considered an irreplaceable metal. One of its main uses is production of
alloys where Cr serves as an anticorrosive and strengthening agent. The main Crcontaining alloy produced is stainless steel. The bright colored Cr salts are used as
pigments in textile dyes, paints, glass, inks and plastics. Other applications that use Cr
compounds are leather tanning, chrome plating, wood preservatives, and refractory
bricks and linings for industrial furnaces.
Some studies have proposed that Cr(III) is an essential nutrient for glucose
metabolism (Schwarz, 1959). However, until this date no disease or negative health
effects have been associated with Cr(III) deficiency (Stearns, 2000). The European
2

Union has recently declared that there is no evidence of beneficial effects associated
with Cr intake in healthy subjects and considers that the setting of an adequate intake for
Cr is not appropriate (European Food Safety Authority, 2014). Cr(III) could potentially
have a therapeutic role in patients with diabetes, but this also remains controversial
(Vincent, 2014). Regarding negative health outcomes, Cr(III) is considered relatively
non-toxic at the doses normally encountered. Cr(VI), on the other hand, is a very toxic
metal and well established human lung carcinogen (IARC, 1990). The first report of a
suspected Cr(VI)-induced tumor was in 1890, an adenocarcinoma in the turbinate body
of a chrome worker (Newman, 1890). Since then, cell culture, animal and
epidemiological studies from workers have provided indisputable evidence for the
carcinogenicity of Cr(VI).

1.3. Cr(VI) Exposure
Cr(VI) is naturally found in soil, air and water, and derives from continental dust
due to weathering and volcanic emissions. However, most of the Cr(VI) found in the
environment has an anthropogenic origin (ATSDR, 2012). Anthropogenic sources
include stationary points such as metal, textile and cement industries, and leather
tanneries. Burning of fossil fuels and waste, and degradation of Cr-containing products
also release Cr(VI). According to the Toxics Release Inventory (ATSDR, 2012), in 2009
about 36 million lbs of Cr compounds were released into U.S. waters, soils and air.
Thus, it is no surprise that Cr is one of the primary pollutants present in 1,127 of the
1,699 sites listed on the Environmental Protection Agency (EPA) National Priorities List
(ATSDR, 2012). Because of its widespread use and presence, exposure to Cr(VI) can
occur through inhalation, ingestion and dermal contact. Of these, inhalation is the main
exposure route.
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Cr is naturally present in meats, fish, vegetables and fruits, as well as grains and
cereals. Cr content in foods is highly variable but it is estimated that mean daily intakes
(i.e.: 60 ug) are within the limits established by the World Health Organization (ATSDR,
2012). Cr(VI) is also present in drinking water. The EPA has an enforceable drinking
standard of 0.1 mg/L for total Cr. However, a 2010 report by the Environmental Working
Group (EWG, 2010) on high Cr(VI) levels in drinking water re-opened the debate on the
potential health effects from oral exposure. It is estimated that most ingested Cr(VI) is
efficiently reduced to non-toxic Cr(III) by gastric acids (De Flora et al., 1997). Cr(III) is
not readily absorbed by cells, making overall Cr(VI) absorption through the
gastrointestinal tract less than 10% of the ingested dose (ATSDR, 2012). Further
reduction in the blood and liver limits the amount of Cr(VI) available for uptake by cells
(De Flora et al., 1997). Due to reduction to Cr(III), Cr(VI) in water has been deemed as
safe. However, the National Toxicology Program (NTP) showed an increase in
neoplasms in the oral cavity in rats and small intestine in mice exposed chronically to
Cr(VI) in drinking water (NTP, 2008). The data on human populations is still
inconclusive. The EPA is currently re-evaluating its standard under the light of the newer
studies.
Dermal exposure to Cr(VI) is possible through direct contact of the skin with
Cr(VI) compounds in industrial settings, Cr(VI)-containing consumer products, as well as
contaminated soils. Skin contact causes irritations and ulcerations. Eczema and
dermatitis are common allergic responses in sensitized individuals. Some compounds
with caustic properties may also induce enough damage to the skin to facilitate entry of
Cr(VI) to the bloodstream and cause systemic toxicity (ATSDR, 2012).
Cr(VI) is also present in Co-Cr-Mo alloys used in prosthetics for joint
replacements. Metal ions and particles released from these replacements are another
potential source of exposure (Jantzen et al., 2013). Although multiple exposure
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scenarios are possible, the greatest risk in both the general public and workers is
through inhalation.
1.3.1. Cr(VI) in the Air
Even though natural sources contribute to atmospheric Cr, about 60-70% of
atmospheric emissions are from anthropogenic sources. Main sources include
combustion of fossil fuels, metal industries, cement plants and incineration of waste.
Johnson et al. (2006) have estimated that worldwide anthropogenic emissions range
between 58 and 112 Gg Cr/yr. It is estimated that a third of the 2,700-2,900 tons of Cr
released into the atmosphere each year in the U.S. is in the hexavalent form (ATSDR,
2012). Cr in the air is mostly in particulate form (Kimbrough et al., 1999). The mass
mean aerodynamic diameter for particles emitted by different industries is <10um
(Kimbrough et al., 1999). It is estimated that particles in this size range can remain
airborne for up to 10 days and be subject to long range transport (Kimbrough et al.,
1999). More importantly, these particles can reach the tracheobronchiolar and alveolar
regions of the lung. Average concentrations from 2,100 monitoring stations in urban,
suburban, and rural areas ranged from 0.005 to 0.525 ug/m3 (EPA 1984, 1990).
1.3.2. Inhalation Exposure in the General Public
The general public is at risk of Cr(VI) inhalation exposure, especially in suburban
and urban areas nearby Cr industries. Home exposures from household dusts are likely
in areas near industrial facilities and waste sites. In 1992-1993, the average Cr
concentration in household dusts from Jersey City, NJ, was 376 ug/g (Freeman et al.,
2000). Jersey City harbors several waste sites from chromate industries and Crcontaminated slag has been extensively used as a landfill in this area. In contrast,
average Cr concentration in household dusts after remediation was 73 ug/g (Freeman et
al., 2000), suggesting that initial high indoor Cr levels were due to higher Cr levels in the
outdoor environment. A similar trend was observed in Cr urine concentrations from
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residents of this area (Stern et al.,1992; Freeman et al., 1995). Home based exposures
can also occur in families of workers through contaminated clothing and shoes (ATSDR,
2012).
Another source of inhaled Cr are cigarettes. Cigarette smoke contains 0.0002-0.5
ug of Cr per cigarette (Smith et al., 1997). Indoor Cr levels in households where smoking
occurs can be 10-400 times greater than those found outside (ATSDR, 2012). Moreover,
because chronic inhalation of cigarette smoking causes lung cancer, the risk of lung
cancer due to Cr(VI) inhalation is expected to be exacerbated in smokers and passivesmokers (Albert, 1991).
1.3.3. Inhalation Exposure in Occupational Settings
The population at greatest risk for Cr(VI) exposure are Cr workers. OSHA
estimates that 558,000 workers in ~80 professions are exposed to Cr(VI) through
inhalation of dusts, fumes and mists (OSHA, 2006). Exposure concentrations are up to
two orders of magnitude higher than the general population (ATSDR, 2012), with the
highest exposures occurring in chromate, chrome pigment, ferrochrome and stainless
steel production, welding and electroplating.
The permissible exposure level (PEL) established by OSHA is an 8 h time
weighted average (TWA) of 5 ug/m3 (OSHA, 2006). However, Cr(VI) concentrations in
ambient air in chromate factories can range from 5-600 ug/m3 (Stern, 1982).
Concentrations have declined significantly since the 1980s due to emission controls
(NTP, 2011).

1.4. Cr(VI) Carcinogenicity
In the 1980s, numerous agencies classified Cr(VI) as carcinogenic to humans
(NTP, 1980; EPA, 1984; NIOSH, 1988; IARC, 1990). This classification derives from
strong evidence in cohorts of workers exposed to Cr(VI). These studies also helped
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establish that the main target for Cr(VI) is the respiratory system. Cr(VI) not only causes
lung cancer, but also induces nasal ulcerations and perforations as well as asthma
(OSHA, 2006). Studies in rats and mice have suggested that the gastrointestinal tract
could be a target for Cr(VI) carcinogenicity (NTP, 2008; Stout et al., 2009). Cr(VI) has
also been shown to enhance UV-induced skin cancer in mice (Davidson et al., 2004;
Uddin et al., 2007). Both the gastrointestinal tract and skin cancer studies are very
recent and the effects on humans are inconclusive. In the below characterization of
Cr(VI) carcinogenicity we will focus only on the respiratory system.
1.4.1. Evidence for Cr(VI) Carcinogenicity
1.4.1.1. Human Studies
The first systematic study on Cr(VI)-induced lung cancer in the United States was
in 1948 (Machle and Gregorious). This study included data from all chromate production
plants in the country and showed that 21.8% of all deaths were due to lung cancer,
compared to 1.3% in a control population. Since then, multiple studies in chromate
workers have provided strong links between Cr(VI) exposure and lung cancer (Hayes et
al., 1979; Mancuso, 1997; Gibb et al., 2000; Luippold et al., 2003). Data collected in
cohorts of chromate pigment production workers, platers and stainless steel welders
also strongly support that Cr(VI) is a lung carcinogen (Sheffet et al., 1982; Langard and
Vigander, 1983; Davies, 1984; Hayes et al., 1989; Moulin, 1997; Sorahan and
Harrington, 2000).
From these studies, it has been estimated that the latency period for diagnosis is
about 15 years (Machle and Gregorious, 1948; Taylor, 1966; Hayes et al., 1979).
Moreover, lung cancer occurrence is correlated with exposure time (Braver et al., 1985).
These studies also show that the particulate Cr(VI) compounds are more carcinogenic
than the soluble ones (Hayes et al., 1979; Alderson et al., 1981). Initially, factories would
add lime (calcium carbonate) to the extraction process to maximize the amount of
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extracted Cr(VI). This would produce high levels of the insoluble calcium chromate. After
the 1950s, factories underwent modernization, installed better hygiene practices and
switched to low-lime or no-lime production. This has greatly reduced the risk of lung
cancer in these cohorts but not completely eliminated it (Hayes et al., 1979; Alderson et
al., 1981; Luippold et al., 2003). In addition, in 2006 OSHA lowered its permissible
exposure limit (PEL) from 52 ug/m3 to 5 ug/m3. The current cohorts have not been
followed long enough but it could be speculated that future epidemiologic studies will
show an even further reduction in the incidence of lung cancers among Cr(VI) workers.
1.4.1.2. Animal Studies
Animal models have also been used to test the carcinogenicity of Cr compounds.
Several Cr compounds of various solubilities have been administered to mice and rats
by inhalation, intrabronchial implantation and intratracheal instillation. These studies also
support that Cr(VI), and not Cr(III), is a lung carcinogen (Nettesheim et al., 1971; Levy
and Vennit, 1986; Steinhoff et al., 1986; Snyder et al., 1997). They also show particulate
forms are more potent carcinogens than the soluble forms (Levy et al., 1986).
1.4.1.3. Cell Culture Studies
Cellular transformation assays, namely loss of contact inhibition and growth in
soft agar, have also been used to test Cr(VI) compounds. Both particulate and soluble
Cr(VI) compounds are able to induce cellular transformation in various cell lines
(Patierno et al., 1988; Elias et al., 1989; Xie et al., 2007; Rodrigues et al., 2009), with the
particulate compounds being more potent than soluble ones (Elias et al., 1989).
Moreover, Cr(VI)-transformed cells form tumors when injected in mice (Elias et al., 1989;
Rodrigues et al., 2009). Studies in cells also show that the dissolution of Cr(VI) particles
is necessary for transformation (Elias et al., 1991). DNA repair deficiency may also play
a role in Cr(VI)-induced cellular transformation (Xie et al., 2008).
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1.4.2. Physico-Chemical Factors Involved in Cr(VI) Carcinogenicity
1.4.2.1. Valence State
The valence state of Cr plays an important role in its carcinogenicity because it
determines its uptake by cells. Cr(III) binds strongly to water and molecules that have
oxygen, nitrogen or sulfur in their structures (Zhitcovich, 2004), forming bulky molecules
that do not readily cross cell membranes. In contrast, Cr(VI) has a tetrahedral structure
that resembles that of phosphate and sulfate, and enters cells by facilitated diffusion
through generic anion transporters (DeFlora and Wetterhahn, 1989). Once inside the
cell, Cr(VI) undergoes reduction to Cr(III), which rapidly accumulates inside of cells
because it is not excreted. Reduction of Cr(VI) to Cr(III) also favors more uptake of
Cr(VI). Moreover, reduction forms Cr(V), Cr(IV) and reactive oxygen species. Both Cr(III)
and reduction intermediates can bind and damage DNA, but it is unknown which of
these is the ultimate carcinogenic species.
1.4.2.2. Reduction
Reduction of Cr(VI) to Cr(III) plays a major role in Cr(VI) carcinogenesis.
Extracellular reduction leads to a protective effect as Cr(III) does not easily enter cells. In
contrast, intracellular reduction forms reactive intermediates that cause DNA damage
(Shi et al., 1999). Cr(VI) can be reduced by numerous reductants including ascorbate,
glutathione, cysteine, lipoic acid and diol-containing molecules such as NADPH (Shi et
al., 1999). Microsomes, mitochondria, cytochrome P-450 and flavoenzymes have also
been shown to reduce Cr(VI) in vitro (Shi et al., 1999). Ascorbate has been proposed to
be the main reductant in the rat lung (Suzuki and Fukuda, 1990; Standeven and
Wetterhahn, 1992). However, these studies were done treating bronchoalveolar lavage
fluid or cytosolic fractions from lung tissues, as opposed to treating whole animals. Rats
also have significantly higher levels of lung ascorbate than humans (Slade et al., 1985)
and can synthesize it while humans cannot. Both of these factors could favor ascorbate
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being the primary reductant in rat lung tissue. Moreover, studies in mice suggest
NADPH, not ascorbate, is the main reductant in vivo (Liu et al., 1994; 1995; Liu and
Dixon, 1996).
1.4.2.3. Solubility
Solubility is another important factor in Cr(VI) carcinogenesis. Multiple
epidemiological studies have shown that the particulate forms are more potent
carcinogens than the soluble forms (Hayes et al., 1979; Alderson et al., 1981).
Moreover, cancer incidence decreased after factories changed to no lime production
which significantly reduces the amount of particulate Cr(VI) compounds that are formed
during chromite processing (Hayes et al., 1979; Alderson et al., 1981, Luippold et al.,
2003). Animal studies also support the carcinogenicity of particulate forms of Cr(VI)
(Levy et al., 1986) and cell culture studies show that they cause neoplastic
transformation (Elias et al., 1987; Patierno et al., 1988; Xie et al., 2007).
Tumors in chromate workers and animal studies have shown that particulate
Cr(VI) impacts lung bifurcation sites where it accumulates (Ishikawa et al., 1994a),
adhering to epithelial cells. Particles dissolve slowly over time creating a prolonged
exposure in the surrounding tissue. Moreover, cell studies suggest that cells enhance
the dissolution of proximate particles, creating high concentrations of chromate anions in
the microenvironment between particles and cells (Wise et al., 1994). This prolonged
exposure causes DNA damage, aneuploidy and neoplastic transformation (Xie et al.,
2005; Holmes et al., 2006a, 2008). In contrast, soluble compounds are rapidly reduced
by the epithelial lining fluid and macrophages and cleared from lungs via the mucociliary
escalator (De Flora and Wetterhahn, 1989; De Flora et al., 1997).
1.4.3. Cr(VI) Genotoxicity
One very important aspect of Cr(VI) carcinogenicity is its genotoxicity. Cr(VI)
itself is not reactive towards DNA. Instead, DNA damage is caused by Cr(V), Cr(IV),
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Cr(III), and/or oxygen- and carbon-based radicals formed during Cr(VI) reduction
(O’Brien et al., 2003). The spectrum of damage includes base substitutions, oxidized
bases, strand breaks, DNA crosslinks, and binary and ternary DNA adducts (DeFlora,
1990; O’Brien et al., 2003). Cr(VI) also induces gross numerical and structural DNA
abnormalities such as aneuploidy, sister chromatid exchanges, chromosome aberrations
and micronuclei (Holmes et al., 2008). Cr(VI) genotoxicity has mostly been investigated
in cell culture models and numerous reviews have summarized this extensive wealth of
data (Leonard and Lauwerys, 1980; De Flora et al., 1990; O’Brien et al., 2003;
Zhitcovich, 2004; Holmes et al., 2008; Wise et al., 2008; Nickens et al., 2010). These
studies highlight the diversity of DNA damage induced by Cr(VI) and the multiple
mechanisms underlying it. In contrast, Cr(III) only damages DNA in in vitro systems but
is not genotoxic in whole cells or animals (De Flora et al., 1990). These data are
consistent with the poor uptake of Cr(III).
1.4.3.1. Oxidative DNA Damage
DNA damage by Cr(VI) can be caused indirectly through the formation of oxygen
and carbon radicals formed during intracellular reduction of Cr(VI) (Yao et al., 2008).
Cr(VI) can generate the carbon-based radical glutathione-derived thiyl radical (GS●)
which forms by reaction of Cr(VI) with GSH (Shi et al., 1999). Cr(V) and Cr(IV) react with
hydrogen peroxide (H2O2) and form hydroxyl radicals (●OH) via a Fenton-like reaction
(Shi et al., 1999). Hydroxyl radicals cause oxidative DNA damage to bases, such as the
common ROS biomarker 8-OHdG, and are responsible for formation of abasic sites and
single strand breaks after Cr(VI) exposure (Casadevall and Kortenkamp, 1995).
However, most of these studies used very high concentrations of Cr(VI) and hence, may
not reflect realistic exposure scenarios. As such, the contribution of these lesions to
Cr(VI) carcinogenesis is still under debate (O’Brien et al., 2003).
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1.4.3.2. DNA Adducts and Crosslinks
The most important lesions caused by Cr(VI) are those where Cr(III) binds
directly to DNA. This is possible due to the presence of six coordination sites on Cr(III)
that stably bind DNA and other ligands with high affinity (Zhitcovich, 2004). Cr binds
DNA specifically on DNA phosphate groups (Zhitcovich et al., 1996). Binding of Cr(III) to
DNA forms binary and ternary Cr-DNA adducts and DNA-DNA interstrand crosslinks
(Zhitcovich, 2004). In particular, Cr(III)-mediated DNA adducts with cysteine, glutathione
and histidine are very abundant and of relevance due to their high mutagenic potential
(Voitkun et al., 1998; Zhitcovich et al., 2001; Quievryn et al., 2003). Cr(III) ternary
adducts cause base substitutions that target G/C pairs and lead to T/A transversions and
A/T transitions (Voitkun et al., 1998, Zhitcovich et al., 2001; Quievryn et al., 2003). The
same mutational spectrum is observed in lungs of Big Blue transgenic mice after
intratracheal instillation of Cr(VI) (Cheng et al., 1998; 2000). Ternary adducts and
interstrand crosslinks can also cause replication arrest due to polymerase stalling at the
sites of the lesions (Bridgewater et al., 1994; O’Brien et al, 2001). Cr-DNA ternary
adducts are repaired by nucleotide excision repair (NER) (Reynolds et al., 2004; O’Brien
et al., 2005). Strikingly, NER deficiency decreases mutagenicity and clastogenicity of
Cr(VI) suggesting a role of NER in Cr(VI)-induced DNA damage (Brooks et al., 2008).
Other studies have shown NER deficient cells exhibit increased apoptosis and
clonogenic lethality after Cr(VI) exposure (Reynolds et al., 2004; O’Brien et al., 2005).
Altogether, the data suggest that a proficient NER may enhance DNA damage and
survival in Cr(VI)-treated cells.
1.4.3.3. DNA Double Strand Breaks
DNA double strand breaks (DSBs) also form after Cr(VI) exposure (Ha et al.,
2004; Xie et al., 2005; Xie et al., 2009) . DSBs caused by Cr(VI) are formed in
asynchronous cell populations and abrogated when cells are arrested at G0/G1 phase
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indicating that DSBs formation after Cr(VI) exposure is dependent on DNA replication
(Ha et al., 2004). Specifically, DSBs form during S and G2 phases likely due to
replication arrest or fork collapse when the replication machinery encounters an adduct
or single strand break (Ha et al., 2004; Reynolds et al., 2007). Mismatch repair (MMR)
has also been implicated in the formation of DSBs after Cr(VI) exposure (Reynolds et al.,
2009). Cells deficient in MMR have less Cr(VI)-induced DSBs as measured by γ-H2A.X
foci formation (Peterson-Roth et al., 2005). DSBs are normally repaired through
homologous recombination (HR) repair which is also involved in the repair of Cr(VI)induced DSBs (Bryant et al., 2006; Xie et al., 2008). Interestingly, chronic exposure to
Cr(VI) in human lung cells inhibits Rad51 foci formation, a key step in HR (Qin et al.,
2014). HR deficiency is very detrimental and leads to neoplastic transformation in Cr(VI)exposed cells (Xie et al., 2007).
1.4.3.4. Structural Chromosome Damage
Failure to repair DNA DSBs can have devastating consequences because
unrepaired DSBs give rise to structural chromosome damage (i.e.: clastogenesis) in the
form of complex chromosome aberrations. Cr(VI) exposure causes chromosome
aberrations after acute and longer exposures in human lung cells (Wise et al., 2002;
Holmes et al., 2006a; Wise et al., 2006a; Wise et al., 2010). For particulate Cr(VI)
compounds, it has been demonstrated that it is the chromate anion and not the cation or
particle that is responsible for the clastogenic effects (Wise et al., 2004a; Xie et al.,
2004).
1.4.3.5. In Vivo Genotoxicity
Genotoxicity assays carried out in workers, mainly platers and welders, using
peripheral blood lymphocytes demonstrate that in vivo Cr(VI) induces micronuclei, strand
breaks, sister chromatid exchanges, chromosome aberrations and crosslinks (IARC,
1990; ATSDR, 2012; O’Brien et al., 2003; Proctor et al., 2014). Oxidative DNA damage
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is also detected after Cr(VI) exposure in humans and animals. Urinary concentrations of
8-hydroxydeoxyguanosine (8-OHdG), a major product of DNA oxidation, are increased
in the urine of Cr(VI) workers and correlate with urinary Cr levels and concentrations of
airborne Cr in factories (Kuo et al., 2003). An increase in 8-OHdG has also been
observed in lung tissue of rats exposed to Cr(VI) by intratracheal instillation or inhalation
(Izotti et al., 1998, Maeng et al., 2003). These studies are in accordance with in vitro and
cell culture studies and reinforce the potent genotoxicity of Cr(VI).
1.4.4. Characteristics of Cr(VI)-Induced Tumors
The analysis of lung tissues from Cr(VI) workers has also contributed to the
understanding of Cr(VI) carcinogenesis. The most common types of Cr(VI)-induced lung
cancer are squamous cell carcinoma and small-cell lung carcinoma (Ishikawa et al.,
1994b). Cr(VI)-induced tumors have a tendency to originate in the central part of the
lung, specifically at bronchial bifurcations. The bifurcation ridges, and in particular the
ridge centers, are hot spots of Cr deposits even 15 years after cessation of exposure
(Ishikawa et al., 1994a). This supports the idea that Cr(VI) particles persist in the lung
and dissolve slowly over time. Cr concentration in the lung ranges from 8-468 ug/g dry
tissue, with highest Cr concentrations in the lungs of workers with lung tumors.
Moreover, Cr accumulation increases with each generation of tracheobronchial
branching and also correlates with the degree of malignancy (Kondo et al., 2003).
Tumors from chromate workers have also been analyzed for expression of key
oncogenes and tumor suppressor genes. Cr(VI)-induced tumors from chromate workers
have fewer p53 mutations and no ras mutations, when compared to lung tumors from
the general population (Kondo et al., 1997; Ewis et al., 2001). These tumors also have
reduced expression of p53, p16INK4a and bcl-2 proteins (Katabami et al., 2000). In
contrast, cyclin D1, a protein that regulates cell cycle progression during G1 phase, is
overexpressed (Katabami et al., 2000). Cr(VI) tumors have also been analyzed for
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proteins related to lung function. Specifically, surfactant protein B (SP-B) variants are
overrepresented in Cr(VI) tumors (Ewis et al., 2006). SP-B is part of the lung surfactant
liquid which coats inhaled particles and aids with mucociliary clearance of the respiratory
tract, among other functions (Akella and Desphande, 2013). Interestingly, these variants
have been shown to increase susceptibility to squamous cell carcinoma in individuals
not exposed to Cr(VI) (Seifart et al., 2002).
Microsatellite instability (MIN) is also a common feature of Cr(VI) tumors (Hirose
et al., 2002). Microsatellites are DNA regions characterized by repetitive short nucleotide
sequences. MIN refers to variations in the number of repetitive unit sequences in
microsatellites caused by defective mismatch repair (MMR) (Loeb, 1994). In a study by
Hirose et al. (2002) 92% of Cr(VI) tumors had MIN in one or more markers compared to
50% found in lung tumors not caused by Cr(VI) exposure. MIN also correlated with
duration of exposure. Expression of MMR proteins hMLH1 and hMSH2 was also
analyzed in the above set of tumors (Takahashi et al., 2005). The repression rate of
hMLH1 and hMSH2 in Cr(VI) lung tumors tumors was 56% and 75%, respectively,
compared to 20% and 23% in non Cr(VI) lung tumors. Hypermethylation of the hMLH1
promoter region could be partially responsible for the decreased expression in Cr(VI)
tumors (Takahashi et al., 2005; Sun et al., 2009).
Cr(VI) has the ability to bind to histones likely through electrostatic interactions
(Levina et al., 2006). It can also crosslink the histone deacetylase 1-DNA
methyltransferase 1 complex to chromatin, specifically to the CYP1A1 promoter region
(Schnekenburger et al., 2007). The above interactions suggest Cr(VI) may be able to
induce epigenetic changes. Kondo et al. (2006) have shown that tumors from chromate
workers have reduced p16INK4a expression which correlates with hypermethylation of
p16INK4a in its promoter region. Hypermethylation of the hMLH1 and APC genes has also
been described (Takahashi et al., 2005; Ali et al., 2011). Overall, the studies suggest
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Cr(VI) tumors have a higher methylation frequency of tumor suppressor genes than lung
tumors not induced by Cr(VI).

1.5. Mechanisms of Cr(VI)-Induced Carcinogenicity
All cancer cells share similar characteristics or “hallmarks” of cancer (Hanahan
and Weinberg, 2000). These include the ability to resist cell death, sustain proliferative
signaling, evade growth suppressors and immune destruction, reprogram energy
metabolism, enable replicative immortality, induce angiogenesis, and activate invasion
and metastasis (Hanahan and Weinberg, 2000; 2011). However, cells can acquire these
hallmarks by different mechanisms, which can currently be summarized through three
carcinogenesis paradigms: multi-stage carcinogenesis, epigenetic modification and
genomic instability.
1.5.1. Multi-Stage Carcinogenesis
The multi-stage carcinogenesis paradigm (Vogelstein and Kinzler, 1993) entails
that mutations in key proto-oncogenes and tumor suppressor genes lead to
tumorigenesis through a step by step process in which each mutation confers the cell a
proliferative advantage as well as aid in tumor progression and malignancy. Under this
paradigm, a chemical carcinogen would need to cause a significant number of mutations
in target genes.
As described before, Cr(VI) causes mutations in cell culture systems. However,
mutation studies often use very high cytotoxic doses that do not reflect likely exposure
scenarios (Holmes et al., 2008). Moreover, the bulk of the mutagenesis data comes from
shuttle vector assays carrying specific Cr-induced lesions. Shuttle vectors are made of
DNA that lacks proteins, nucleosomes and overall chromatin structure. As such, the host
cell DNA repair machinery might act differently on these lesions than on those formed on
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genomic DNA. Given these considerations, it is possible that these studies may
overestimate Cr(VI) mutagenesis.
In addition, Cr(VI)-induced tumors do not show frequent mutations in key genes
such as ras and p53 (Kondo et al., 1997; Ewis et al., 2001). This is in discordance with
the multistage carcinogenesis paradigm. It is also very different than what is commonly
observed in other lung tumors where ras is mutated in 20-30% of tumors, while p53 is
mutated in 50-90% (Mitsuuchi and Testa, 2002). This striking difference suggests Cr(VI)induced carcinogenesis does not involve mutagenesis as a central mechanism.
1.5.2. Epigenetics
In the epigenetic paradigm, the driving forces for tumorigenesis are epigenetic
changes. Epigenetic changes refer to heritable changes in the genome that do not
involve changes in the DNA sequence (Feinberg, 2004). These include cytosine
methylation, post-translational modifications on histones and changes in chromatin
structure or organization (Feinberg, 2004). The ability of Cr(VI) to induce epigenetic
changes has been studied in cell lines as well as tumors.
A set of lung tumors from Japanese chromate workers was analyzed for
methylation changes at different genes involved in DNA repair and cell cycle. Overall,
these tumors had hypermethylation of p16INK4, hMLH1 and APC genes (Kondo et al.,
2006; Ali et al., 2011). In the case of p16INK4 and hMLH1, hypermethylation correlated
with decreased protein expression (Kondo et al., 2006; Ali et al., 2011). Wang et al.
(2012) analyzed global methylation in a cohort of chromate workers from China using
DNA extracted from blood. They showed global DNA hypomethylation which correlated
with the presence of urinary 8-OHdG and DNA strand breaks in peripheral lymphocytes.
Cell culture studies also show evidence of epigenetic changes by Cr(VI). Klein et
al. (2002) used a transgenic Chinese hamster cell lung model to analyze methylation
status of the transgene gpt after Cr(VI) treatment. Cr(VI) caused partial methylation of
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the gpt reporter and silenced the expression of the gpt gene. Mouse Hepa-1 cells were
co-exposed to Cr(VI) and benzo[a]pyrene [B(a)P]), a carcinogen that induces gene
expression through the aryl hydrocarbon receptor (AhR). Cr(VI) caused crosslinking of
histone deacetylase 1-DNA methyltransferase 1 complex to the CYP1A1 promoter,
inhibiting histone and acetylation marks usually induced by transactivation of the AhR
(Schnekenburger et al., 2007). Cr(VI) also increases global H3K9 di and tri methylation
in A549 cells and BEAS-2B cell lines (Sun et al., 2009). Moreover, the methylation
patterns are localized to specific regions of the nucleus, with H3K9 dimethylation being
mostly peripheral and H3K9 trimethylation localizing to the central region of the nucleus.
Increased levels of methyltransferase G9a might be responsible for increased H3K9
dimethlyation seen after Cr(VI) exposure (Sun et al., 2009). In the case of H3K9
dimethylation, methylation was enriched in the promoter region of hMLH1, which
correlated with decreased hMLH1 mRNA levels. Similar results have been observed in
Cr(VI) tumors (Hirose et al., 2002; Ali et al., 2011).
Overall, the data from these studies show Cr(VI) is able to induce epigenetic
changes in cell lines and human subjects. More importantly, epigenetic changes are
observed in Cr(VI) tumors. The timing of these changes, either early or late, in the
carcinogenesis process is currently unknown. In addition, it is very likely that for these
changes to have an effect they would have to be permanent or present for long periods
of time. The cell culture studies were mostly done with short time exposures which may
not reflect the more realistic, chronic exposure scenarios. Even if changes are
permanent, they might not be able to transform cells on their own. Given that Cr(VI) is a
potent genotoxicant, epigenetic changes could exacerbate Cr(VI)-induced DNA damage
by affecting proteins involved in DNA repair. Together, the currently available epigenetic
data cannot explain the carcinogenicity of Cr(VI).
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1.5.3. Genomic Instability
The genomic instability paradigm supports that disruption of the processes that
maintain the stability of the genome leads to an accelerated rate of genetic changes at a
whole genome level (Lengauer et al., 1998). There are two types of genomic instability,
microsatellite

and

chromosomal

instability.

Microsatellite

instability

(MIN)

is

characterized by changes in the lengths of microsatellites, DNA regions with repetitive
short nucleotide sequences (Loeb, 1994). Chromosome instability (CIN) involves gain or
losses of partial or whole chromosomes (Lengauer et al., 1998).
1.5.3.1. Microsatellite Instability (MIN)
Microsatellites are prone to mutations due to replication errors caused by
polymerases at these regions (Karran, 1996). Polymerases can sometimes add the
wrong nucleotide or stutter or slip causing insertion or deletion loops. These lesions if left
unrepaired result in base substitutions and changes in the length of microsatellites. In
normal cells, insertion/deletion loops and base pair mismatches are fixed by mismatch
repair (MMR). If MMR is defective, the replication lesions are not fixed and cells acquire
MIN (Karran, 1996).
MIN has been described in lung tumors from Cr(VI)-exposed workers (Hirose et
al., 2002). MIN of two or more loci was observed in 79% of these tumors, compared to
15% in controls. A higher frequency of MIN was also associated with longer exposure
time and repression of the MMR protein hMLH1 (Hirose et al., 2002; Takahashi et al.,
2005). Decreased expression of hMLH1 has also been observed in human lung cells
after Cr(VI) exposure (Sun et al., 2009). Cell culture studies have also reported that
deficient MMR might enhance survival and prevent apoptosis due to decreased DNA
double strand break formation (Peterson-Roth et al., 2005; Reynolds et al., 2007).
Interestingly, MMR might also be involved in potentiating Cr(VI)-induced DNA double
strand breaks through the repair of Cr-DNA adducts (Peterson-Roth et al., 2005;
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Reynolds et al., 2007, 2009; Reynolds and Zhitkovich, 2007). These data suggest MMR
might play dual roles in Cr(VI) toxicity and together with the tumor data pinpoint MMR
and MIN as important mechanisms in Cr(VI) carcinogenesis.
1.5.3.2. Chromosome Instability (CIN)
Exposure to Cr(VI) also causes CIN. CIN refers to an increased rate of gain or
losses of partial or whole chromosomes (Lengauer et al., 1998). Numerical CIN
specifically refers to gain or losses of whole chromosomes, while structural CIN refers to
DNA breaks and translocations, insertions and deletions (Lengauer et al., 1998). CIN is
very common in solid tumors, including those of the lung, and accounts for their gross
karyotype abnormalities (Testa et al., 1992; Lengauer et al., 1998).
Numerical CIN has not been analyzed in Cr(VI) tumors or investigated using in
vivo models. However, chromosome losses and gains are common in lung tumors of
different etiology (Balsara and Testa, 1992; Testa et al., 1992). Near triploid and
tetraploid complements are also frequent (Balsara and Testa, 1992; Testa et al., 1992).
Cell culture studies show Cr(VI) is able to induce numerical CIN in human lung cells. A
soluble form of Cr(VI), potassium dichromate, was able to induce aneuploidy in the form
of hypodiploidy (i.e.: less than 2N) after a 30 h treatment (Güerci et al., 2000; Seoane et
al., 2002). Particulate forms of Cr(VI) have also been studied. Both lead and zinc
chromate induced aneuploidy, in the forms of hypodiploidy, hyperdiploidy and
tetraploidy, after chronic exposure (i.e.: 48-120 h) (Holmes et al., 2006b; Holmes et al.,
2010). Lead chromate-induced aneuploid cells were able to survive and form colonies
suggesting that the phenotype is persistent (Holmes et al., 2006b). In support of this,
human lung epithelial cells transformed by lead chromate also show increased
aneuploidy (Xie et al., 2007).
Structural CIN is also very prevalent in lung tumors (Balsara and Testa, 1992;
Testa et al., 1992). It is indicated by the presence of chromosomal translocations,
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insertions and deletions. No studies have analyzed these events in Cr(VI) tumors or
using in vivo models. However, chromosomal aberrations that can lead to structural CIN
have been studied extensively using the chromosome damage, sister chromatid
exchange and micronucleus assays. These studies show that Cr(VI), both soluble and
particulate forms, can cause multiple chromosomal aberrations in human lung fibroblasts
and epithelial cells (Wise et al., 2002; Wise et al., 2004a; Holmes et al., 2006a; Wise et
al., 2006a; Reynolds et al., 2007; Wise et al., 2010). In the case of lead chromate, it was
also shown that it is the chromate anion and not the lead cation or internalized particles
that cause chromosomal aberrations (Wise et al., 2004a; Xie et al., 2004). Micronuclei
and sister chromatid exchanges after Cr(VI) exposure have also been described in nonhuman cell lines (ATSDR, 2012). Animal studies have mostly analyzed micronuclei
formation, and have yielded both positive and negative results (ATSDR, 2012).
However, these studies used intraperitoneal or oral exposure of soluble compounds,
which are not good models for studying Cr(VI) lung carcinogenesis. Increased frequency
of micronuclei, sister chromatid exchanges and chromosomal aberrations have been
observed in peripheral blood lymphocytes of Cr(VI) workers (IARC, 1990; ATSDR,
2012). The ultimate DNA lesion leading to structural CIN are DNA double strand breaks
(DSBs). Intratracheal instillation of sodium dichromate in the lungs of rats induced DNA
fragmentation measured by DNA electrophoresis (Izotti et al., 1998). DNA DSBs,
measured by the comet assay and γ.H2AX foci formation, also form in human lung cells
after Cr(VI) exposure (Xie et al., 2004; 2009; Ha et al., 2004; Wakeman et al., 2004;
Reynolds et al., 2007a, Wise et al., 2010).
In summary, human, animal and cell culture studies show Cr(VI) causes both
MIN as well as numerical and structural CIN. Even though, the underlying causes are
still unknown, the above studies strongly support that genomic instability is a feasible
mechanism for Cr(VI) carcinogenesis.
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1.6. Mechanisms Involved in Chromosome Instability
Multiple mechanisms have been implicated in the acquisition of a CIN phenotype.
These include chromosome condensation, sister chromatid cohesion, kinetochore
structure and function, cell cycle checkpoints, DNA repair, centrosome duplication and
microtubule formation and dynamics (Langauer et al., 1998; Negrini et al., 2010).
Despite great advances in the understanding of the molecular basis of each of these
mechanisms, our current knowledge of how they contribute to genomic instability and
tumorigenesis is still very limited.
1.6.1. Possible Mechanisms Underlying Cr(VI)-Induced CIN
Our understanding of how Cr(VI) causes genomic instability is also very limited.
However, a few studies have begun to help elucidate the complexity of Cr(VI)
carcinogenesis. Human lung cells exposed to lead and zinc chromate show a timedependent and concentration-dependent increase in centrosome amplification (Holmes
et al., 2006b, Holmes et al., 2010). Centrosomes are major contributors to numerical
CIN. Cr(VI)-treated cells show evidence of bypass of the spindle checkpoint that controls
proper microtubule-kinetochore attachments (Wise et al., 2006b; Holmes et al., 2010).
Spindle checkpoint bypass leads to abnormal mitotic phenotypes such as premature
anaphase, premature centromere division and centromere spreading, which also cause
numerical CIN (Holmes et al., 2010b). Moreover, these phenotypes suggest potential
defects in the cohesion of sister chromatids. At the molecular level, Cr(VI) decreases
expression of spindle checkpoint proteins Mad2 and Cdc20 (Holmes et al., 2010; Karri et
al., 2013). It also decreases Cdc20 localization to kinetochores and the interaction of
Cdc20 with Mad2 (Karri et al., 2013). The above studies show that Cr(VI) can alter
pathways that control numerical stability of the genome.
Exposure to Cr(VI) also affects DNA repair pathways involved in maintaining
structural CIN. Qin et al. (2014) have shown that chronic exposure to Cr(VI) decreases
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expression of homologous recombination (HR) repair proteins as well as RAD51 foci
formation. Interestingly, this decreased response is followed by overexpression of nonhomologous end joining proteins, an alternative DNA DSB repair pathway that is more
error-prone than HR (Qin, 2013). Moreover, HR deficient cell lines exposed to Cr(VI)
have increased structural CIN and neoplastic transformation (Bryant et al., 2006;
Stackpole et al., 2007; Xie et al., 2008). The data from these studies indicate that
inhibition of key DNA repair pathways contribute to structural CIN observed after Cr(VI)
exposure.
Figure 1.1. shows our proposed model for Cr(VI) carcinogenicity based on our
current knowledge of Cr(VI) genotoxicity and its effects on cellular molecular pathways.
This project focuses specifically on centrosome amplification and attempts to investigate
how Cr(VI) causes this phenotype.
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Figure 1.1. Mechanism for Cr(VI) Carcinogenesis. This figure shows a proposed
mechanism of how Cr(VI) induces cancer. A cell is exposed to particulate Cr(VI) (1).
Particles can be phagocytosed but they have no effect (2,3). Alternatively, the particle
dissolves extracellularly into the cation and chromate anion [Cr(VI)] (4,5). The cation
enters cells through calcium channels but has no effect (6,7). The chromate anion enters
cells by facilitated diffusion using the generic anion transporter (8). Once inside, Cr(VI) is
reduced to Cr(V), Cr(IV) and Cr(III) (9). The reduction also generates reactive radicals
(9). Both Cr intermediates and reactive radicals damage DNA, ultimately forming DNA
DSBs (10). Cells arrest in G2 phase and attempt to repair the damage (11). However,
Cr(VI) suppresses HR repair (12) and activates NHEJ repair (13). This switch from an
error-free to an error-prone repair pathway leads to structural CIN (14). The reduction
intermediates (9) can also cause other types of damage that manifest as centrosome
amplification, spindle assembly checkpoint bypass and defects in sister chromatid
cohesion (15). These abnormalities contribute to numerical CIN (16). Structural and
numerical CIN (14, 16) are permanent and heritable phenotypes (17) and cause
neoplastic transformation (18). The growth of neoplastically transformed cells forms a
tumor and leads to cancer (18).
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1.7. The Centrosome
In 1902 Theodor Boveri, one of the fathers of genetics, postulated that cancer
cells arose from chromosomal imbalances due to multipolar spindles (Boveri, 1902;
Wunderlich, 2002). This was the first theory on the genetic origin of cancer and still
prevails after 100+ years. Boveri also named an organelle that had a central position in
the cell as the centrosome and proposed that abnormal duplication of centrosomes lead
to the chromosomal imbalances in cancer cells (Wunderlich, 2002). A century later, we
now know that centrosome abnormalities are indeed frequent in tumors and contribute to
tumorigenesis (D’Assoro et al., 2002; Chan, 2011).
Centrosomes are small organelles, 1-2 um3 in volume, that nucleate and
organize microtubules. Microtubules are one of the building blocks for the cell’s
cytoskeleton, which regulates cell size, shape, adhesion, polarity, and migration, as well
as intracellular transport. Centrosomes also nucleate the microtubules that form the
mitotic spindle, and as such, play a major role in proper chromosome segregation and
cytokinesis. Centrosomes also serve as signaling centers for control of cell cycle
progression (Doxsey, 2001).
Structurally, each centrosome is composed of two centrioles in orthogonal
position embedded in a matrix of proteins named the pericentriolar material (PCM)
(Figure 1.2). Centrioles resemble open-ended cylinders which are formed by nine triplets
of microtubules. The main functions of centrioles are to regulate the duplication of the
centrosome and serve as a core for building the PCM (Marshall, 2007). The PCM holds
γ-tubulin ring complexes which act as a base template for microtubule nucleation (Moritz
et al., 1995). The two centrioles are structurally different and one centriole has
appendages on its distal end while the other does not. Accordingly, centrioles are
referred to as mother and daughter, respectively.
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Figure 1.2. The Centrosome. This figure shows the basic composition of a centrosome.
At the center, there are two centrioles arranged in an orthogonal position. Each centriole
is a cylinder-like structure formed by nine triplets of microtubules. Their distal end
contains the protein centrin, commonly used as a centrin marker. The “mother” centriole
is distinguished by the presence of distal and sub-distal appendages. Centrioles are
embedded in the pericentriolar material (PCM), a highly organized matrix of proteins.

1.7.1. Centrosome Duplication and the Centrosome Cycle
When a cell enters a new cell cycle, in G1 phase, it has one centrosome.
However, this centrosome must be duplicated once, and only once, before mitosis.
Centrosome duplication ensures a correct number of centrosomes for bipolar orientation
of the mitotic spindle and for the future two daughter cells. To guarantee proper
centrosome duplication, the centrosome cycle is tightly regulated and coordinated with
overall cell cycle progression (Sluder, 2005).
The centrosome cycle (Fig 1.3) begins as cells enter G1 phase. The first step
involves the separation of mother and daughter centrioles and is referred to as centriole
disengagement (Tsou and Stearns, 2006a). Initially, both centrioles still share the same
PCM but as G1 progresses, each centriole acquires its individual PCM. Centriole
duplication begins at the G1/S phase transition, as each disengaged centriole begins to
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grow a procentriole from the proximal end and in an orthogonal position (Robbins et al.,
1968; Kuriyama and Borisy, 1981). Centriole duplication requires activity of Cdk2-Cyclin
A/E and Plk4 (Lacey et al., 1999; Matsumoto et al., 1999; Hadenback et al., 2005).
Procentrioles elongate during S and G2 phases until they reach full length (i.e.: 0.5 um).
During G2, the PCM achieves greater capacity for microtubule nucleation, a process
termed centrosome maturation. Up to this phase, both centrosomes remain attached to
each other and serve as one microtubule organizing center (MTOC). At the G2/M
transition, they are split away from each other through the action of the Nek2 kinase (Fry
et al., 1998a; Faragher and Fry, 2003). The motor protein Eg5 separates both
centrosomes by pushing them apart (Blangy et al, 1995). Centrosome separation begins
during prophase and establishes the bipolarity of the mitotic spindle (Mardin and
Schiebel, 2012). At the end of mitosis, cytokinesis yields two daughter cells, with one
centrosome each.
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Figure 1.3. The Centrosome Cycle. This figure shows the main steps involved in the
centrosome cycle. The cycle begins in G1 phase with the disengagement of mother and
daughter centrioles. Each disengaged centriole duplicates a new centriole during S
phase. These newly formed centrioles elongate during G2 phase. In G2, centrosomes
mature and acquire greater microtubule nucleating capacity. At the G2/M transition,
duplicated centrosomes split. During prophase they separate from each other and form
the bipolar spindle.

1.7.2. The Centriole Linkers
An important aspect of the centrosome cycle is the formation of protein linkers
between the centrioles. These linkers form and split at specific phases of the cell cycle
and serve to coordinate centrosome cycle events with events at the cell cycle level.
There are two centriole linkers: the S-M linker and the G1-G2 tether (Nigg and Stearns,
2011).
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1.7.2.1. The S-M Linker and Regulation of Centriole Disengagement
The S-M linker is formed in S phase and splits as cells exit mitosis (M), hence its
name (Nigg and Stearns, 2011). It is formed between a mother centriole and the
centriole that grows perpendicular from it during S phase. The purpose of this linker is to
keep mother and daughter centrioles engaged throughout the cell cycle. Centriole
disengagement is only needed in G1 phase to allow for a new round of duplication.
A small set of proteins have been implicated as being part of the S-M linker
(Figure 1.4). Cohesin (Nakamura et al., 2009; Schöckel et al., 2011), the same protein
complex that holds sister chromatids together, was shown to localize to centrosomes
(Guan et al., 2008; Nakamura et al., 2009). Moreover, depletion of Scc1, a cohesin
subunit, causes premature centriole disengagement in mitosis (Nakamura et al., 2009).
A small form of Shugoshin (Sgo), sSgo, also localizes to centrosomes and might
function in protecting cohesin from premature cleavage (Wang et al., 2008). Cells with
silenced Sgo1 show centriole disengagement in mitosis that is rescued by
overexpression of sSgo1 (Wang et al., 2008). Kendrin/Pericentrin B, a component of the
pericentriolar material, may also provide external support to keep the centrioles engaged
(Lee and Rhee, 2012; Matsuo et al., 2012). Centriole disengagement was inhibited in
cells with depleted Pericentrin B and rescued with a cleavage-resistant mutant protein.
However, cells rescued with wild type protein showed centriole disengagement (Lee and
Rhee, 2012).
Upstream of cohesin, sSgo and Pericentrin B, is the protease separase.
Separase activity is regulated by the degradation of its inhibitor, securin (Cohen et al.,
1996; Ciosk et al., 1998). Securin binding blocks the access to the active site of
separase (Waizenegger et al., 2002). Upon securin degradation, separase is free to
cleave substrates. Among its substrates, is the cohesin subunit Scc1 (Nakamura et al.,
2009; Schöckel et al., 2011). Ectopic activation of separase causes premature centriole
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disengagement, which can be prevented by expression of a non-cleavable form of Scc1
(Schöckel et al., 2011). Separase has also been shown to cleave Pericentrin B (Lee and
Rhee, 2012; Matsuo et al., 2012).

Figure 1.4. The S-M Linker. This figure shows the components of the S-M linker. Mother
and daughter centrioles are immersed in the pericentrolar material and engaged to each
other through cohesin rings. A small variant of Shugoshin (sSgo) protects cohesin from
degradation. Pericentrin B, a PCM protein, wraps around the mother centriole providing
further support and engagement.
1.7.2.2. The G1-G2 Tether and Centrosome Separation
As mentioned earlier, at the beginning of G1 phase the S-M linker splits and
mother and daughter centrioles disengage. However, they become reconnected through
a new linker. This linker is named G1-G2 tether, as it forms in G1 phase and remains
present until G2 phase (Nigg and Stearns, 2011). Given that the disengaged mother and
daughter centrioles will each form a new centrosome, the G1-G2 tether serves the
purpose to keep these two centrosomes together until mitosis. Even though the cell has
two centrosomes, because they are connected, they will behave as one microtubule
organizing center (Nigg and Stearns, 2011).
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The G1-G2 tether is established between the proximal ends of centrioles and it
involves the proteins C-Nap1, Rootletin, Cep135, Cep68, LRRC35 and Centlein, (Fry et
al., 1998b; Bahe et al., 2005; Graser et al., 2007; Kim et al., 2008; He et al., 2013; Hardy
et al., 2014; Fang et al., 2014) (Figure 1.5). C-Nap1 is a coiled-coiled protein that
localizes to the free proximal end of centrioles (Fry et al., 1998b). This interaction
appears to be mediated through Cep135, which also localizes to the free proximal end of
centrioles (Kim et al., 2008; Hardy et al., 2014). C-Nap1 serves as a docking site for
Rootletin, LRRC35 and Cep68 which form a fiber-like structure that holds the
centrosomes together (Bahe et al., 2005; Graser et al., 2007; He et al., 2013). C-Nap1
interacts directly with Rootletin fibers (Yang et al., 2006). Interaction of C-Nap1 and
Cep68 is indirect and mediated through a protein named Centlein (Fang et al., 2014).
The G1-G2 tether is split at the G2/M transition (Fry et al., 1998a; Faragher and
Fry 2003). The kinase NIMA-related kinase 2 (Nek2) phosphorylates C-Nap1, Rootletin,
LRRC45 proteins causing them to dissociate from centrosomes (Mayor et al., 2002;
Bahe et al., 2005; Mardin et al., 2010; He et al., 2013). Nek2 activation is due to
autophosphorylation (Fry et al., 1995; Helps et al., 2000) but its ability to remain active
depends on multiple proteins. Nek2 is in a complex with protein phosphatase 1 (PP1)
and mammalian sterile 20-like kinase (Mst2) (Helps et al., 2000; Mardin et al, 2011).
PP1 dephosphorylates Nek2, as well as Nek2 substrates such as C-Nap1 (Helps et al.,
2000). However, phosphorylation of Mst2 by Polo like kinase 1 (Plk1) prevents binding of
PP1 to the Nek2-Mst2 complex (Mardin et al., 2011). Under this scenario, the complex is
released from its inhibitory partner allowing Nek2 to remain active and phosphorylate the
linker components. Once the G1-G2 tether is split at the G2/M transition, centrosomes
are free to separate in prophase (Mardin et al., 2011). Centrosome separation is an
active process and requires the activity of the motor protein Eg5 (Blangy et al., 1995).
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Centrosome separation positions centrosomes in opposite poles of the cell and allows
for proper bipolar spindle formation (Tanembaum and Medema, 2010).

Figure 1.5. The G1-G2 Tether. This figure shows the proteins that form the G1-G2
tether. Cep135 localizes to the proximal end of centrioles C-Nap 1 interacts with Cep135
and serves as a docking site for the formation of fibers made by Rootletin, Cep68 and
LRRC45. C-Nap1 interacts directly with Rootletin and possibly LRRC45. However, the
interaction with Cep68 is indirect through Centlein.
1.7.2.3. Importance of the Centriole Linkers
The two different linkers formed between centrioles serve to coordinate
centrosome cycle events with cell cycle events (Nigg and Stearns, 2011; Mardin and
Schiebel, 2012). The S-M linker keeps mother and daughter centrioles together until the
next cell cycle when centrioles are required to disengage in order to be duplicated. The
G1-G2 tether retains newly duplicated centrosomes close to each other until their
separation is needed during prophase. Multiple studies have shown that untimely
disruption of the centriole linkers can lead to deleterious phenotypes. Premature
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centriole disengagement has been extensively linked to centrosome amplification
(Maiato and Logarinho, 2014). Delayed centrosome separation causes an increase in
the time spent in mitosis which leads to chromosome segregation errors due to improper
attachments between kinetochores and microtubules (Indjeian and Murray, 2007;
Kaseda et al, 2012; Mchedlishvilli et al., 2012; Silkworth et al., 2012). In contrast,
premature centrosome separation has been shown to enhance proliferation and survival
which in a normal cell might not be problematic, but in a genetically unstable cell could
contribute to tumor growth (Mardin et al., 2013). These studies shed some light on the
potential roles of the centriole linkers as well as emphasize the importance of proper
timing of centriole disengagegent and centrosome separation.
1.7.3. Role of Centrosomes in Carcinogenesis
It is very important that cells duplicate their centrosome once and only once
during the cell cycle. Proper regulation and timing of the centrosome cycle is key in
maintaining a normal number of centrosomes (Doxsey, 2002). Abnormalities in the
centrosome cycle can lead to centrosome amplification (CA), a phenotype where cells
acquire greater than two centrosomes. Extra centrosomes are a problem because they
form multipolar spindles or bipolar spindles with multiple centrosomes at each pole,
causing improper attachment of microtubules to the kinetochores and unequal
segregation of DNA (Doxsey 2002; Sluder and Nordberg 2004). This can result in
chromosome instability, a major driving force for tumorigenesis (D’Assoro et al, 2002;
Fukasawa, 2005, Pihan et al, 2003).
Centrosome amplification is commonly found in human tumors and tumorderived cell lines (Pihan et al., 1998; Chan, 2011). Abnormalities in size, shape and
position are also frequent (Pihan et al., 1998; Chan, 2011). Centrosome amplification
and other centrosomal defects are also present in pre-invasive carcinomas suggesting
that centrosome abnormalities are an early event in tumorigenesis (Pihan et al., 2003).
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In addition, centrosome defects are increased in higher degree in situ carcinomas
suggesting that these defects play a role in the progression of pre-cancerous lesions
(Pihan et al., 2001; Pihan et al., 2003).
Lung tumors also exhibit centrosome amplification. Pihan et al. (1998) analyzed
a series of malignant tumors from different tissues, including lung. All tumor cells from
the lung tumor had centrosome amplification while none was observed in non-tumor
cells (Pihan et al., 1998). In non-small cell lung cancers (NSCLC), Jung et al. (2007) also
observed abnormalities in number, size and shape of centrosomes in 29% of the tumors
analyzed. In addition, 93% of the tumors with centrosome abnormalities were aneuploid,
supporting the idea that centrosome defects cause numerical CIN (Jung et al., 2007).
Interestingly, cells surrounding the lung tumor also showed early signs of centrosome
abnormalities. Koutsami et al. (2006) also analyzed NSCLC tissues. They observed
centrosome amplification and structural defects of centrosomes in 53% of the samples.
A positive correlation with aneuploidy was also established. Similar to the Jung et al.
(2007) study, centrosome amplification and defects were present in adjacent
hyperplastic regions as well. These studies suggest that centrosome abnormalities are
common and early events in lung carcinogenesis. Their prevalence and early
appearance likely contribute to the widespread CIN observed in lung tumors and lung
tumor-derived cell lines (Balsara et al., 1992; Haruki et al., 2001, Masuda and
Takahashi, 2002).

1.8. Metal-Induced Centrosome Amplification
Centrosome amplification and associated defects, such as spindle polarity, have
been studied in different cell lines exposed to inorganic and organic forms of metals.
These studies and their main findings are summarized in Table 1.1 and most have also
been previously reviewed by Holmes and Wise (2010). The majority of the studies on
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metals and centrosomes have focused on arsenic. Both inorganic arsenic as well as
organic species, such as dimethylarsinic acid, induce centrosome amplification and
aneuploidy (Debec et al., 1990; Ochi, 2000; 2002a; Ochi et al., 1999a; 1999b; 2003;
2004; 2008; Yih et al., 2006; 2012; Liao et al., 2007; 2010; Wu et al., 2013). It appears
that arsenic-induced centrosome amplification happens in cells during a prolonged
mitotic arrest due to activation of the spindle checkpoint and involves fragmentation of
the PCM, as centrosomes lack centrioles (Yih et al., 2006). Inorganic lead and mercury
do not cause centrosome amplification but inorganic cadmium induces abnormal mitosis
with scattered chromosomes (Debec et al., 1990; Ochi, 2002b; Holmes et al., 2006b).
Interestingly, organic mercury, in the form of methylmercuric chloride, causes
centrosome amplification and multipolar spindles but the mechanism is unknown (Ochi,
2002b). Metals in nanoparticle forms have also been considered. Titanium dioxide
nanoparticles cause centrosome amplification in NIH/3T3 cells (Huang et al., 2009). The
increase in the number of bi- and multinucleated cells suggests that failure of cytokinesis
might be the underlying mechanism. Organic and inorganic forms of vanadium did not
cause centrosome amplification but instead induced the formation of monopolar spindles
which pinpoints to a lack of centrosome separation during mitosis (Navara et al., 2001).
In summary, these studies emphasize that centrosome amplification is a common
phenotype after exposure to metals. They also highlight differences in mechanisms,
which is not surprising giving that these metals cause toxicity through very different
mechanisms.
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Table 1.1. Summary of Studies on Metal-Induced Centrosomal Defects.
Treatment

CoTreatment
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Assay

Cell Type

Summary of Effects

Reference

Arsenite
75 uM
0-42 h

Immunofluorescence for
centrosomes and
microtubules

Kc23 Drosophila
embryonic cell line

Acentrosomal cells, disruption of
microtubules
(less quantity).

Debec et
al., 1990

Arsenite
5-10 um
20-24 h

Acridine orange stain and
immunofluorescence for
microtubules

V79 chinese
hamster lung
fibroblasts

No effect on multinucleated cells or
microtubule network.

Ochi et al.,
1999a

Sodium arsenite
3-10 uM
48 h

Flow cytometry

Syrian hamster
embryo cells

Hypo and hyperdiploidy.

Ochi et al.,
2004

Sodium arsenite
2 uM
3-24 h

Immunofluorescence for
centrosomes,
microtubules, dynein and
NuMA

CGL-2

Centrosome amplification in mitotic
cells, acentriolar centrosomes or
with abnormal number of centrioles,
decreased dynein localization,
increased NuMA expression.

Yih et al.,
2006

Sodium arsenite
2 uM
1-16 h

Western blot for dynein
and NuMA

CGL-2

Increased NuMA protein levels, no
changes in dynein.

Yih et al.
2006

Sodium arsenite
2 uM
1-16 h

siRNA for BubR1 and
Mad2

CGL-2

Spindle checkpoint is crucial for
centrosome amplification, mitotic
arrest leads to CA.

Yih et al.
2006

Immunofluorescence for
centrosomes

BEAS-2B

Centrosome amplification in p53
compromised cells, cells grew in
soft agar.

Liao et al.,
2007

Sodium arsenite
1-10 uM
48 h

Pifithrinalpha (p53
inhibitor) 20
uM
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Table 1.1. Continued.
Treatment

CoTreatment

Assay

Sodium arsenite
1-5 uM
48 h

NNK 1-5
uM

Immunofluorescence for
microtubules

Sodium arsenite
1 uM
1-4 weeks

Cell Type

Summary of Effects

Reference

BEAS-2B

Centrosome amplification when
cells are co-treated with As and
NNK in a p53 compromised status
(not seen if As or NNK are alone).

Liao et al.,
2010

Immunofluorescence for
microtubules and Aurora A

HaCaT

Time lapse microscopy

EYP-tubulin HeLa

Immunofluorescence for
microtubules

CGL-2

Immunofluorescence for
centrosomes and
microtubules

V79 chinese
hamster lung
fibroblasts

Arsenic trioxide
3uM
40 h

37
Arsenic trioxide
1 uM
20-24 h

Dimethylarsinic
acid
1-10 mM
6-12 h

Y-27632
5-10 uM
(ROCK
inhibitor)

37

Multinucleated cells, aberrant
chromosome segregation, multiple
centrosomes, aberrant distribution
of Aurora A.
Disruption of the proper positioning
of the spindle and induces
centrosome and spindle
abnormalities, in the form of
multipolar spindles. These cells
arrest at mitosis and undergo
apoptosis.
Spindle mis-positioning, ROCK
inhibition reduces spindle
abnormalities, arsenic may induce
defects in mitotic spindles PIP4KIIγmediated activation of the
Rho/ROCK pathway.
Centrosome amplification and
multipolar spindles, loss of
microtubule network.

Wu et al.,
2013

Yih et al.,
2012

Yih et al.,
2012

Ochi et al.,
1999a

Table 1.1. Continued.
Treatment

CoTreatment

Assay

Cell Type

Summary of Effects

Reference

Dimethylarsinic
acid
2 mM
24 h

Videograph analysis

V79 chinese
hamster lung
fibroblasts

Cells become multinucleated
without dividing into two daughter
cells.

Ochi et al.,
1999b

Dimethylarsinic
acid
2 mM
24 h

Acridine orange stain

V79 chinese
hamster lung
fibroblasts

Multinucleated cells.

Ochi et al.,
1999b

Dimethylarsinic
acid
2-10 mM
6-20 h

Immunofluorescence for
microtubules

V79 chinese
hamster lung
fibroblasts

Disappearance of microtubule
network in interphase cells and
aberrant mitotic spindles.

Ochi et al.,
1999b
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Dimethylarsinic
acid
5-10 mM
6h

1 um
Nocodazole
or 2 um
Cytochalasin B

Immunofluorescence for
centrosomes and
microtubules

V79 chinese
hamster lung
fibroblasts

Multipolar spindles in mitotic cells,
microtubule network required to
induce centrosome amplification.

Ochi, 2000

Dimethylarsinic
acid
8mM
6h

0.5 mM
Orthovanadate

Immunofluorescence for
centrosomes and dynein

V79 chinese
hamster lung
fibroblasts

Multiple centrosomes, dynein not
involved.

Ochi, 2002a

Dimethylarsinic
acid
8mM
6h

200 uM
Monastrol

Immunofluorescence for
centrosomes and
microtubules

V79 chinese
hamster lung
fibroblasts

Kinesin might play a role in the
induction of multiple centrosomes.

Ochi, 2002a
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Table 1.1. Continued.
Treatment

CoTreatment

Assay

Cell Type

Summary of Effects

Reference

Dimethylarsinic
acid
0.1-2 mM
10-24 h

Immunofluorescence for
centrosomes and
microtubules

V79 chinese
hamster lung
fibroblasts

Centrosome amplification and
multipolar division in telophase.

Ochi et al.,
2003

Dimethylarsine
iodide
0.125-0.5 mM
3-32 h

Immunofluorescence for
centrosomes and
microtubules, Giemsa
staining and acridine
orange staining

V79 chinese
hamster lung
fibroblasts

Centrosome amplification, multipolar
mitosis, aneuploidy, multinucleate
cells, disruption of microtubule
network.

Ochi et al.,
2003
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Dimethylarsine
iodide
0.25-1 uM
2-48 h

30 uM
Nocodazole

Immunofluorescence for
centrosomes and
microtubules, flow
cytometry

Syrian hamster
embryo cells

Multipolar spindles, inhibition of
microtubule re-growth, hypo and
hyperdiploidy.

Ochi et al.,
2004

Thiodimethylarsenite
0.01-0.2 mM
48 h

1 mM BSO

Immunofluorescence for
centrosomes,
microtubules

HepG2

Centrosome amplification which may
require GSH.

Ochi et al.,
2008

Cadmium
chloride
10-100 uM
0-24 h

Immunofluorescence for
centrosomes and
microtubules

Kc23 Drosophila
embryonic cell
line

Abnormal mitosis with scattered
chromosomes.

Debec et
al., 1990

Lead chromate
0.1-1 ug/cm2
24-120h

Immunofluorescence for
centrosomes,
microtubules

WTHBF-6 human
lung fibroblasts

Centrosome amplification caused by
chromium, not lead.

Holmes et
al., 2006b
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Table 1.1. Continued.
Treatment

CoTreatment
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Assay

Cell Type

Lead chromate
1-10 ug/cm2
120 h

Immunofluorescence for
centrosomes, microtubules

BEP2D (foci
derived cell lines)

Zinc chromate
0.1-0.2 ug/cm2
24-120 h

Immunofluorescence for
centrosomes, centrioles
and microtubules

WTHBF-6 human
lung fibroblasts

Lead oxide
0.1-10 ug/cm2
24-120 h

Immunofluorescence for
centrosomes, microtubules

WTHBF-6 human
lung fibroblasts

No centrosome amplification.

Holmes et
al., 2006b

Mercuric
chloride
0.5-10 uM
6-24 h

Immunofluorescence for
centrosomes and
microtubules

V79 chinese
hamster lung
fibroblasts

No effects on centrosome number
or spindles.

Ochi, 2002b

Methylmercuric
chloride
0.05-2.5 uM
6-30 h

Immunofluorescence for
centrosomes and
microtubules

V79 chinese
hamster lung
fibroblasts

Multinucleated cells and
centrosome amplification with
multipolar spindles.

Ochi, 2002b

NIH/3T3

Centrosome amplification, bi- and
multinucleated cells and aneuploidy,
failure of cytokinesis due to
misregulation of Plk1 might be a
mechanism.

Huang et
al., 2009

Titanium dioxide
nanoparticles
10 ug/ml
12 weeks

Nocodazole

Immunofluorescence for
microtubules and Plk1
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Summary of Effects
3/10 foci had centrosome
amplification in interphase cells;
7/10 foci had centrosome
amplification in mitotic cells.
Centrosome amplification in
interphase and mitotic cells, caused
by multiple mechanisms: multiple
rounds of centrosome duplication,
centriole splitting and acentriolar
centrosome formation.

Reference
Xie et al.,
2007

Holmes et
al., 2010

Table 1.1. Continued.
Treatment

CoTreatment

Assay

Cell Type

Summary of Effects

Reference

Vanadocene
acetylacetonate
0.3 uM
24 h

Immunofluorescence for
centrosomes and
microtubules

BT-20 breast
cancer cell line

Monopolar spindles (did not count
how many centrosomes).

Navara et
al., 2001

Vanadocene
dichloride
25 uM
24 h

Immunofluorescence for
centrosomes and
microtubules

BT-20 breast
cancer cell line

Monopolar spindles formed by two
centrosomes.

Navara et
al., 2001
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1.8.1. Cr(VI)-Induced Centrosome Amplification
An increase in the number of cells with extra centrosomes (i.e.: centrosome
amplification) is observed after prolonged exposure (i.e.: 48-120 h) to particulate Cr(VI)
compounds (Holmes et al., 2006b; Holmes et al., 2010). Centrosome amplification is
present in both interphase and mitotic cells and is characterized by acentriolar
centrosomes and cells with supernumerary centrioles (Holmes et al., 2010). The
presence of different centrosome phenotypes suggests that multiple mechanisms
underlie Cr(VI)-induced centrosome amplification. Lung epithelial cells neoplastically
transformed by lead chromate also exhibit centrosome amplification (Xie et al., 2007).
Moreover, centrosome amplification is also present in lung tumors from chromate
workers that died of lung cancer (Holmes, 2011).

1.9. Summary
Cr(VI) is potent human lung carcinogen that most likely causes cancer through a
genetic instability mechanism. Cr(VI) particles enter the lungs through inhalation and
deposit at bifurcation sites where they persist. They slowly dissolve over time and as
they do the chromate anions readily enter surrounding cells through generic anion
transporters. Once inside the cells, Cr(VI) is reduced to Cr(III). Reduction forms Cr(V),
Cr(IV) and reactive oxygen and carbon species. Reduction intermediates as well as
Cr(III) are capable of reacting with DNA causing complex lesions such as adducts,
crosslinks and DNA double strand breaks. These lesions lead to structural chromosome
instability.
Cr(VI) also induces numerical chromosomal instability but the underlying
mechanism is not known. Centrosomes have long been implicated in maintaining proper
chromosome numbers due to their involvement in mitotic spindle formation and
positioning. As a result, centrosome duplication is tightly regulated to ensure that the cell
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only has two centrosomes at mitosis. Errors in centrosome duplication can lead to
centrosome amplification (i.e.: extra centrosomes), causing chromosome missegregation
which contributes to numerical chromosome instability. Centrosome amplification is very
common in solid tumors, including those of the lung, and is considered a major driving
force for tumorigenesis.
Centrosome amplification has also been observed in human lung cells exposed
to Cr(VI). Cr(VI)-induced centrosome amplification appears to be complex, as it has
been shown that multiple mechanisms might be involved in its formation. However, the
centrosomal proteins and pathways affected by Cr(VI) remain elusive. Given that the
centriole linkers are crucial for proper timing of centrosome cycle events and centrosome
duplication, this project investigates Cr(VI) effects on the S-M linker and the G1-tether.
Our hypothesis is that exposure to Cr(VI) causes premature splitting of the S-M linker
and G1-G2 tether causing centrosome amplification.
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CHAPTER 2
MATERIALS AND METHODS

2.1. Materials
2.1.1. Cell Culture
Dulbecco’s Minimal Essential Medium and Ham’s F-12 (DMEM/F-12) 50:50
mixture, Dulbecco’s Phosphate Buffered Saline 1x (PBS), penicillin/streptomycin and
glutaGRO were purchased from Mediatech, Inc. (Manassas, VA). Cosmic calf serum
was purchased from HyClone (Logan, UT). 0.25% Trypsin/EDTA was purchased from
Gibco (Grand Island, NY). Sodium pyruvate was purchased from Lonza (Walkersville,
MD). Tissue culture dishes, flasks, and plasticware were purchased from BD (Franklin
Lakes, NJ). MycoAlert mycoplasma detection kits were purchased from Lonza Rockland,
Inc. (Rockland, ME). CO2 tanks were purchased from Airgas (Salem, NH) and Matheson
(South Portland, ME). Cloning cylinders were purchased from Scienceware (Wayne,
NJ).
2.1.2. Particulate Cr(VI) Compounds
Zinc chromate (ZnCrO4, CAS # 13530-65-9) was purchased from Sigma Aldrich
(St. Louis, MO) and Pfaltz & Bauer, Inc. (Waterbury, CT). Lead chromate (PbCrO 4, CAS
# 7758-97-6) was purchased from Sigma Aldrich (St. Louis, MO).
2.1.3. Numerical Chromosome Instability Assay
Demecolcine was purchased from Sigma Aldrich (St. Louis, MO). KCl and acetic
acid were purchased from J.T. Baker (Phillipsburg, NJ). Methanol was purchased from
BDH (Radnor, PA). Gurr’s buffer was purchased from LifeTechnologies (Carslbad, CA).
Giemsa stain was purchased from Ricca Chemical Co. (Arlington, TX). Richard Allan
Scientific Super Up-Rite microscope slides and Cytoseal 60 slide mounting medium
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were purchased from Thermo Scientific (Waltham, MA). Coverslips were purchased from
VWR (Radnor, PA).
2.1.4. Immunocytochemistry
Lab Tek II glass chamber slides were purchased from Thermo Scientific
(Waltham, MA). FNC coating mix was purchased from AthenaES (Baltimore, MD).
Coverslips were purchased from VWR (Radnor, PA). Methanol was purchased from
BDH (Radnor, PA). Acetone, MgSO4, and KCl were purchased from J.T. Baker
(Phillipsburg, NJ). 4% paraformaldehyde in PBS was purchased from Alfa Aesar (Ward
Hill, MA). 10x PBS was purchased from Mediatech, Inc. (Manassas, VA). Goat serum
was purchased from Life Technologies (Carslbad, CA). Glycerol, fish skin gelatin, Triton
X-100, EDTA, PIPES and sodium azide were purchased from Sigma Aldrich (St. Louis,
MO). BSA was purchased from EMD Millipore (Billerica, MA). ProLong Gold Antifade
Reagent with DAPI and Alexa Fluor secondary antibodies were purchased Life
Technologies (Carlsbad, CA). DyLight secondary antibodies were purchased from
Jackson ImmunoResearch (West Grove, PA)
2.1.5. Western Blots
Glycine, NaCl, BSA, DTT and PMSF were purchased from EMD Millipore
(Billerica, MA). Tris base was purchased from Amresco (Solon, OH). SDS and KCl were
purchased from J.T. Baker (Phillipsburg, NJ). HCl was purchased from VWR (Radnor,
PA). 30% acrylamide/BIS solution, ammonium persulfate, Tween-20, Quick Start BSA
Standard, Quick Start Bradford Reagent, 0.45 um nitrocellulose membranes, 0.2 um
ImmunBlot PVDF membranes, and HRP-conjugated goat anti-mouse and anti-rabbit IgG
antibodies were purchased from BioRad (Hercules, CA). HEPES solution was
purchased from American Bioanalytical (Natick, MA). EDTA, MgCl2, MnCl2, TEMED, 2mercaptoethanol, and IGEPAL CA-630 were purchased from Sigma Aldrich (St. Louis,
MO). PhosSTOP and cOmplete ULTRA phosphatase and protease inhibitor cocktail
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tablets were purchased from Roche (Indianapolis, Indiana). Isopropyl alcohol was
purchased from Avantor Performance Materials (Center Valley, PA). Odyssey blocking
buffer was purchased from Li-Cor (Lincoln, NE). IRDye800 goat anti-mouse antibody
was purchased from Rockland Inc. (Boyertown, PA). Alexa Fluor 680 goat anti-rabbit
antibody and Tris-Glycine SDS 2x sample buffer were purchased from Life Technologies
(Carlsbad, CA). RIPA Lysis Buffer System was purchased from Santa Cruz
Biotechnology (Dallas, TX). Pierce ECL2 Western Blotting Substrate, PageRuler Plus
Prestained Protein Ladder and PageRuler Prestained NIR Protein Ladder were
purchased from Thermo Scientific (Waltham, MA).

2.2. Cells and Cell Culture
The majority of Cr(VI)-induced lung tumors are classified as squamous cell
carcinomas (Ishikawa, 1994b), hence they are of epithelial origin. However, epithelial
cells are difficult to culture and passage for extended periods of time. Fibroblasts are key
components of the stroma underlying the epithelia (Kalluri and Zeisberg, 2006). They are
associated with epithelial cells throughout all stages of the carcinogenic process and
contribute to it by producing oncogenic signals, facilitating angiogenesis and potentially
playing a role in metastasis (Kalluri and Zeisberg, 2006). Moreover, for Cr(VI)-induced
lung tumors, Kondo et al. (2003) have shown that Cr(VI) accumulates in the bronchial
stroma and not the epithelium. Hence, we used a fibroblast cell line, WTHBF-6 for all of
our experiments. WTHBF-6 is an immortalized clonal cell line derived from primary
human bronchial fibroblasts (PHBF) (Wise et al., 2004b). These cells have a stable and
normal karyotype, normal growth parameters and respond similarly to Cr(VI) as the
primary human cells that they are derived from. WTHBF-6 cells were maintained as
adherent sub-confluent monolayers in DMEM/F-12 supplemented with 15% cosmic calf
serum, 0.2 mM L-alanyl-L-glutamine, 0.1 mM sodium pyruvate, 100 IU/ml penicillin and
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100 ug/ml streptomycin. Cells were fed three times a week, split at least once a week,
and tested for mycoplasma contamination once a month. All cells and experiments were
maintained in a 37°C, humidified incubator with 5% CO2.

2.3. Zinc and Lead Chromate Preparation
Zinc and lead chromate were prepared according to our published methods
(Wise et al., 2002). Briefly, zinc and lead chromate powders were washed twice in
distilled water followed by two washes with acetone to remove soluble and organic
impurities, respectively, and left to dry. The night before treatment, 0.042 g of either zinc
or lead chromate were suspended in 10 ml of cold, filter-sterilized water. The suspension
was stirred overnight at 4°C with a magnetic stir bar to break up large particles. The
following day dilutions were made as needed. A vortex mixer was used to maintain
particles in suspension while making dilutions.

2.4. Cell Treatments
Zinc and lead chromate were administered as a suspension of particles in cold
sterile water according to our published methods (Wise et al., 2002). Logarithmically
growing cells were seeded and allowed to rest for 48 hours. The media was changed
and cells were treated for 24, 72 and 120 hours with a concentration range of 0.1, 0.15
and 0.2 ug/cm2 of zinc chromate and 0.5 ug/cm2 of lead chromate. A vortex mixer was
used to maintain particles in suspension during treatments. Concentrations are
expressed in ug/cm2 to reflect treatment with a particulate compound and to account for
undissolved particles. At the end of treatment time, cells were harvested as specified for
each experiment type.
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2.5. Clonal Expansion Assay
Our laboratory has also developed clonal cell lines that survived Cr(VI) exposure.
These clones were treated with lead chromate for 24 h three times separated by one
month intervals (Wise, 2013). Cells were seeded in 6-well plates, allowed to rest for 48 h
and treated with 5 ug/cm2 lead chromate for 24 h. At the end of treatment, cells were
harvested and re-seeded at colony forming density (i.e.: 1000 cells per 100 mm dish).
Once colonies formed (~2 weeks), they were ring-cloned and expanded into cell lines.
These cell lines were treated for 24 h and cloned again. The resulting cell lines
underwent treatment and cloning process one more time. A set of untreated cells were
also expanded and cloned. Control and treated clonal cell lines were analyzed for
centrosome amplification. These cell lines have also been karytyoped and characterized
for their ability to growth in soft agar and their DNA repair efficiency (Wise, 2013). We
used these clonal cell lines to assess the persistence of the centrosome amplification
phenotype.

2.6. Numerical Chromosome Instability Assay
Numerical chromosome instability (CIN) was analyzed by staining metaphases
and counting the number of chromosomes in 100 metaphases, as described in Holmes
et al. (2006a). Briefly, cells seeded in 100 mm dishes were treated with 0, 0.1, 0.15 and
0.2 ug/cm2 zinc chromate for 24, 72 and 120 h. An hour before the end of treatment,
demecolcine, a microtubule depolymerizing agent, was added to arrest the cells in
metaphase. At harvest, media was collected and cells were washed with PBS,
trypsinized and spun down for 5 min at 1000 RPM in a 4°C centrifuge. The pellet was
resuspended and incubated for 17 min in a 0.075 KCl hypotonic solution to swell cells.
One ml of 3:1 methanol: acetic acid fix was added and cells were spun down. The pellet
was resuspended in fix and incubated for 20 min at room temperature. The fix was
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changed two more times and cells were dropped onto wet slides. Slides were dried
overnight and stained for 5 minutes with 5% Giemsa stain. Dry slides were coverslipped
using Cytoseal 60. Metaphases were observed under a 100x objective with an Olympus
light microscope. At least three independent experiments were performed. Cells that
deviated from the normal diploid number (i.e.: 2N=46 chromosomes) were classified as
having numerical CIN.

2.7. Immunocytochemistry
2.7.1. Centrosome Amplification Analysis
To quantify the number of centrosomes in zinc chromate-treated cells, cells were
treated and stained for γ-tubulin, a marker for the pericentriolar material, and α-tubulin, a
component of microtubules, as described by Holmes et al. (2006b). Cells were seeded
on 1-well glass chamber slides coated with FNC coating mix and treated with 0, 0.1,
0.15 and 0.2 ug/cm2 zinc chromate for 24, 72 and 120 h. At harvest, cells were washed
with a microtubule stabilizing buffer (3 mM EGTA, 50 mM PIPES, 1mM MgSO4, 25 mM
KCl), fixed with -20°C methanol for 10 minutes, air dried for 5 min, permeabilized with
0.05% Triton X-100 for 3 minutes and blocked for 30 minutes in centrosome blocking
buffer (5% goat serum, 1% glycerol, 0.1% BSA, 0.1% fish skin gelatin and 0.04% sodium
azide in 1x PBS). After blocking, cells were incubated for 1 h at room temperature with
anti-γ-tubulin antibody (T6557, Sigma-Aldrich, St. Louis, MO), washed with PBS and
incubated in the dark for 1 h at room temperature with Alexa Fluor 555 secondary
antibody. This was followed by washing and incubation in the dark for 1 h at room
temperature with anti-α-tubulin-FITC conjugated antibody (F2168, Sigma-Aldrich, St.
Louis, MO). Cells were washed, left to dry and coverslips were mounted with DAPI.
Centrosome

numbers

in

100

mitotic

cells
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and

1000

interphase

cells

per

concentration/time point were analyzed under a 100x objective using an Olympus BX51
fluorescence microscope. Three independent experiments were performed.
2.7.2. Centrin Analysis
Multiple mechanisms can cause centrosome amplification (Fukasawa, 2005).
These give rise to different phenotypes that can be visualized by staining centrioles with
centrin, a protein found in the distal centriole lumen (Paoletti et al., 1996). Zinc
chromate-treated cells were stained with centrin and γ-tubulin as described by Holmes et
al. (2010). Cells were seeded on 1-well glass chamber slides coated with FNC coating
mix and treated with 0 and 0.2 ug/cm2 zinc chromate for 24, 72 and 120 h. At harvest,
cells were washed with a microtubule stabilizing buffer, fixed with -20°C methanol for 10
minutes, air dried for 5 min, permeabilized with 0.05% Triton X-100 for 3 minutes and
blocked for 30 minutes in centrosome blocking buffer. After blocking, cells were
incubated for 1 h at room temperature with anti-γ-tubulin (T6557, Sigma-Aldrich, St.
Louis, MO) and anti-centrin (gift from Dr. Jeffrey Salisbury, Mayo Clinic, Rochester, MN)
antibodies, washed with 0.05% Triton X-100 and incubated in the dark for 1 h at room
temperature with isotype-specific DyLight 488 and 549 secondary antibodies. Cells were
washed, air-dried and coverslips were mounted with DAPI. Centrosome and centriole
numbers in 50 mitotic cells and 200 interphase cells per concentration/time point were
analyzed under a 100x objective using an Olympus BX51 fluorescent microscope.
Centrosome and centriole numbers were used to assess the presence of supernumerary
centrioles as well as quantify evidence for centriole disengagement. Three independent
experiments were performed.
2.7.3. Centriole Disengagement Analysis
To confirm abnormal centriole disengagement in zinc chromate-treated cells, we
used the ratio of centrin to C-Nap1 foci (Tsou and Stearns, 2006b). C-Nap1 is a protein
present at the free, proximal end of centrioles. Engaged centrioles have a ratio of 2:1 of
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centrin:C-Nap1, while disengaged centrioles exhibit a ratio of 1:1 (Tsou and Stearns,
2006b). Cells seeded on 4 well glass chamber slides coated with FNC coating mix were
treated with 0, 0.1, 0.15 and 0.2 ug/cm2 zinc chromate for 24, 72 and 120 h. After
treatment, cells were washed with PBS and fixed with -20°C methanol and acetone for
10 and 1 min, respectively. Cells were re-hydrated with PBS and incubated with anticentrin antibody (#04-1624, Millipore, Billerica, MA) overnight at 4°C. The following
morning cells were washed with PBS and incubated with anti-C-Nap1 antibody (144981-AP, Proteintech, Chicago, IL) for 1 h at room temperature, followed by washing and
incubation for 1 h at room temperature with anti-γ-tubulin antibody (T6557, SigmaAldrich, St. Louis, MO). Cells were washed and incubated in the dark with isotypespecific DyLight 488, Alexa Fluor 555 and Alexa Fluor 633 secondary antibodies. After
washing and air-drying cells, coverslips were mounted with DAPI. A total of 100
interphase and 50 mitotic cells with a normal centrin number (2 centrin foci for G1 cells
and 4 centrin foci for S/G2/mitotic cells) were analyzed per concentration/time point
using a 100x objective and a BX51 Olympus fluorescence microscope equipped with a
GenASIs Capture & Analysis System (Applied Spectral Imaging, Inc., Carlsbad, CA).
Since Alexa 633 dyes are not visible to the human eye, we used the GenASIs camera
and software to visualize the γ-tubulin signal on a computer screen. Three independent
experiments were performed.
For the previous experiment, the assumption was made that all interphase cells
with 4 centrioles were in S or G2 phase. To further confirm this data we measured
centriole disengagement in zinc chromate-treated cells stained with cyclin D1. Cyclin D1
is expressed at high levels in G1 cells, where it localizes to the nucleus (Baldin et al.,
1993). Thus, cyclin D1 nuclear staining is commonly used as a G1 phase marker. Cells
were seeded on 2 well glass slides coated with FNC coating mix and treated with 0 and
0.2 ug/cm2 zinc chromate for 24, 72 and 120 h. Cells were harvested and fixed as
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above. After rehydration with PBS, they were incubated with anti-centrin antibody (#041624, Millipore, Billerica, MA) overnight at 4°C. The following morning cells were washed
with PBS and incubated with anti-Cyclin D1 antibody (sc-8396, Santa Cruz
Biotechnology, Inc., Dallas, TX) for 1 h at room temperature, followed by washing and
incubation for 1 h at room temperature with anti-C-Nap1 antibody (14498-1-AP,
Proteintech, Chicago, IL). Cells were washed and incubated in the dark with isotypespecific DyLight 488, Alexa Fluor 594 and Alexa Fluor 633 secondary antibodies. After
washing and letting cells dry, coverslips were mounted with DAPI. Centrin numbers were
analyzed in 100 interphase cells with nuclear cyclin D1 staining per concentration/time
point. Three independent experiments were performed.
2.7.4. Centrosome Separation Measurements
Duplicated centrosomes formed in S-phase are normally held together by a
protein linker. This linker is severed at the G2/M transition and allows for centrosomes to
separate in prophase (Mardin and Schiebel, 2012). Depletion of linker proteins by siRNA
caused increased centriole disengagement when cells were exposed to a DNA
damaging agent (Conroy et al., 2012). This suggests that this linker may also help in
protecting centriole engagement. Since zinc chromate is a strong DNA damaging agent
(Xie et al., 2009) and causes centriole disengagement, we hypothesized that exposure
might also disrupt this linker. Hence, we measured centrosome separation in interphase
cells under the premise that if this linker is severed, centrosomes would prematurely
separate in interphase. Cells were seeded on 1 well glass chamber slides coated with
FNC coating mix and treated with 0, 0.1, 0.15 and 0.2 ug/cm2 zinc chromate for 24, 72
and 120 h. At harvest, cells were washed with a microtubule stabilizing buffer, fixed with
-20°C methanol for 10 minutes, air dried for 5 min, permeabilized with 0.05% Triton X100 for 3 minutes and blocked for 30 minutes in centrosome blocking buffer. After
blocking, cells were incubated for 1 h at room temperature with anti-γ-tubulin (T6557,
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Sigma-Aldrich, St. Louis, MO), washed with PBS and incubated in the dark for 1 h at
room temperature with Alexa Fluor 555 secondary antibody. Cells were washed, airdried and coverslips were mounted with DAPI. Pictures of one hundred interphase cells
per concentration/time point were taken using a Nikon Eclipse Ti confocal microscope.
The distance between centrosomes was measured using the Nikon NIS Elements
software. Centrosomes were classified as separated when the distance between them
was >2 μm (Mayor et al., 2000).Three independent experiments were performed.
2.7.5. Nek2 Localization at Centrosomes
Disruption of the centrosome linker at the G2/M transition requires centrosomal
localization and activity of the kinase Nek2A (Fry et al., 1998a; Fry et al., 1998b;
Faragher and Fry, 2003; Bahe et al., 2005). Accordingly, we tested the effects of zinc
chromate on Nek2 localization to the centrosomes. Cells were seeded on 1 well glass
chamber slides coated with FNC coating mix and treated with 0, 0.1, 0.15 and 0.2
ug/cm2 zinc chromate for 24, 72 and 120 h. At harvest, cells were washed with a
microtubule stabilizing buffer, fixed with -20°C methanol for 10 minutes, air dried for 5
min, permeabilized with 0.05% Triton X-100 for 3 minutes and blocked for 30 minutes in
centrosome blocking buffer. After blocking, cells were incubated overnight at 4°C with
anti-Nek2 antibody (sc-55602, Santa Cruz Biotechnology Inc., Dallas, TX). The following
day cell were washed with PBS and incubated at room temperature for 1 h with anti-γtubulin antibody (T6557, Sigma-Aldrich, St. Louis, MO). After washing, cells were
incubated with Alexa 488 and 555 secondary antibodies for 1 h at room temperature.
Cells were washed, air-dried and coverslips were mounted with DAPI. Nek2 localization
to centrosomes was analyzed in one hundred interphase cells per concentration/time
point using an Olympus BX51 fluorescence microscope. Three independent experiments
were performed.
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2.7.6. Eg5 Localization to Microtubules
Following disruption of the centrosome linker, centrosomes are separated from
each other by a pushing force that is generated through the interaction of motor protein
Eg5 with microtubules (Blangy et al., 1995). To further analyze centrosome separation,
we tested the effects of zinc chromate on Eg5 localization to microtubules. Cells were
seeded on 1 well glass chamber slides coated with FNC coating mix and treated with 0,
0.1, 0.15 and 0.2 ug/cm2 zinc chromate for 24, 72 and 120 h. At harvest, cells were
washed with a microtubule stabilizing buffer, fixed with -20°C methanol for 10 minutes,
air dried for 5 min, permeabilized with 0.05% Triton X-100 for 3 minutes and blocked for
30 minutes in centrosome blocking buffer. After blocking, cells were incubated overnight
at 4°C with anti-Eg5 antibody (sc-374212, Santa Cruz Biotechnology Inc., Dallas, TX).
The following day cell were washed with PBS and incubated at room temperature for 1 h
with Alexa 555 secondary antibody. This was followed by washing and incubation in the
dark for 1 h at room temperature with anti-α-tubulin-FITC conjugated antibody (F2168,
Sigma-Aldrich, St. Louis, MO). Cells were washed, air-dried and coverslips were
mounted with DAPI. Eg5 localization to microtubules was analyzed in 50 mitotic cells
and 100 interphase cells per concentration/time point under a 100x objective using an
Olympus BX51 fluorescence microscope. Three independent experiments were
performed.

2.8. Western Blots
2.8.1. Whole Cell Lysates for Analysis of Nek2
Nek2 protein levels were analyzed in whole cell lysates after zinc chromate
treatment. Cells were seeded on 100 mm dishes and treated with 0, 0.1, 0.15 and 0.2
ug/cm2 zinc chromate for 24, 72 and 120 h. At harvest, whole cell lysates were prepared
by washing and collecting cells in cold PBS and centrifuging at 4°C and 14,000 RPM for
54

5 minutes. The pellet was resupended in RIPA Lysis Buffer System and incubated for 15
min on ice. After centrifugation at 4°C and 14,000 RPM for 10 min, supernatants were
mixed with Tris-Glycine SDS Sample Buffer 2x with 5% 2-mercaptoethanol, and boiled
for 5 min at 90-100°C. Protein concentrations were determined using a BSA standard
curve and Synergy HT microplate reader (BioTek, Winooski, VT). Samples (10 μg) were
resolved in 10% acrylamide/bis gels and electrophoresis buffer (25 mM Tris, 192 mM
glycine, 0.1 % SDS) at 100V using a Mini-PROTEAN 3 Cell System (Bio-Rad, Hercules,
CA). Proteins were transferred to nitrocellulose membranes for 2 h at 100 V with ice cold
transfer buffer (25 mM Tris, 192 mM glycine, 20 % methanol) using a Mini Trans-Blot
Cell (Bio-Rad, Hercules, CA). Membranes were blocked with 5% milk and incubated
overnight at 4°C with anti-Nek2 antibody (610594, BD, Franklin Lakes, NJ). The
following day they were washed with 1X TBS/0.1% Tween-20 and incubated for 1 h at
room temperature with an HRP-conjugated secondary antibody (170-6516, Bio Rad,
Hercules, CA). After washing, membranes were incubated with Pierce ECL2 Western
Blotting Substrate and scanned with a Storm 840 Imaging System (GE Healthcare Life
Sciences, Piscataway, NJ). Bands were quantified using ImageQuant TL software (GE
Healthcare Life Sciences, Piscataway, NJ). Equal protein loading was confirmed by
blotting for GAPDH (ab8245, Abcam, Cambridge, MA). Normalized values were
calculated by dividing Nek2 values over GAPDH values for each concentration/time
point. Final protein levels were calculated by dividing the normalized values from
treatments over those from the control. Two independent experiments were performed.
2.8.2. Cell Fractionation for Analysis of Plk1, Eg5, Securin, and Separase
2.8.2.1. Mitotic Shakeoff
Proteins involved in centriole disengagement and centrosome separation are
usually found at high levels during mitosis. These high levels could potentially mask the
effects of zinc chromate in interphase cells. In order to better assess the effects of zinc
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chromate on centriole disengagement proteins, we separated mitotic from interphase
cells. Cells were seeded in T150 cell culture flasks and treated with 0 and 0.2 ug/cm2
zinc chromate for 24, 72 and 120 h. At the end of treatment, the media was saved and
PBS was added to each flask. Flasks were shaken vigorously by hand during 10 minutes
each. Mitotic cells are rounded-up and loosely attached to the bottom of the flask, so
when shaking they detach and float. Floating cells were recovered and mixed with
previously saved media and centrifuged at 4°C and 1000 RPM for 5 min. After
centrifuging, cells were washed once with PBS and centrifuged again. Pellets were
resupended in 1 ml of PBS, transferred to microcentrifuge tubes and centrifuged at 4°C
for 5 min at 14,000 RPM. Cell pellets were stored at -80°C until lysis. Before
centrifuging, a 20 ul sample of the cell suspension in PBS was used to count the number
of cells. These samples were loaded in Cellometer Cell Counting Chambers and
counted using a Cellometer Vision Image Cytometer and Software (Nexcelom
Bioscience LLC, Lawrence, MA). Cell numbers are used to estimate the amount of lysis
buffer added for protein extraction.
The remaining attached cells in the flasks (interphase cells) were detached using
0.25% trypsin/EDTA. The trypsin was quenched with cell culture media and cells were
centrifuged as above. Pellets were washed with PBS twice, resupended in 2 ml of PBS
and transferred to microcentrifuge tubes. Cell suspensions were centrifuged at 4°C for 5
min at 14,000 RPM. Cell pellets were stored at -80°C until lysis. Before centrifugation, a
20 ul sample of the suspensions were used for cell number quantification, as explained
for mitotic cells.
2.8.2.2. Lysis of Interphase and Mitotic Fractions
Mitotic and interphase cell pellets were thawed on ice and resuspended in a mild
lysis buffer (modified from Fry et al., 1997) (50 mM HEPES-KOH, pH 7.4, 5 mM MnCl2,
10 mM MgCl2, 2mM EDTA, 100 mM NaCl, 5 mM KCl and 0.1% (v/v) IGEPAL with
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protease and phosphatase inhibitors). Suspensions were incubated on ice for 30 min
and sheared through a 27½ G needle seven times. This was done while tubes were on
ice to dissipate the heat produced by the shearing. After shearing, the lysates were
centrifuged at 4°C and 14,000 RPM for 10 min. After centrifugation supernatants were
mixed with Tris-Glycine SDS Sample Buffer 2x with 5% 2-mercaptoethanol, and boiled
for 5 min at 90-100°C. Protein concentrations were determined using a BSA standard
curve and Synergy HT microplate reader (BioTek, Winooski, VT).
2.8.3. Plk1 and phospho-Plk1 Western Blots
Mitotic and interphase whole cell lysates (5 ug-10 ug) were resolved in 10%
acrylamide/bis gels and electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1 %
SDS) at 100V using a Mini-PROTEAN 3 Cell System (Bio-Rad, Hercules, CA). Proteins
were transferred to PVDF membranes for 2 h at 100 V with ice cold transfer buffer (25
mM Tris, 192 mM glycine, 20 % methanol) using a Mini Trans-Blot Cell (Bio-Rad,
Hercules, CA). Membranes were blocked with Odyssey blocking buffer and incubated
overnight at 4°C with anti-Plk1 (ab14210, abcam, Cambridge, MA) and anti-phosphoPlk1 (T210) (KAP-CC107, Stressgen, Ann Arbor, MI) antibodies. The following day they
were washed with 1X TBS/0.1% Tween-20 and incubated for 1 h at room temperature
with Alexa Fluor 680 and IRDye800 secondary antibodies for 1 h at room temperature in
the dark. After washing, membranes were scanned with an Odyssey Infrared Imaging
System (Li-Cor Biosciences, Lincoln, NE). Bands were quantified using Odyssey
software (Li-Cor Biosciences, Lincoln, NE). Equal protein loading was confirmed by
blotting for B-actin (GT5412, GeneTex Inc., Irvine, CA). Normalized values were
calculated by dividing Plk1 and phospho-Plk1 values over B-actin values for each
concentration/time point. Final protein levels were calculated by dividing the normalized
values from treatments over those from the control. Phospho-Plk1 to Plk1 ratios were
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calculated by dividing final protein levels for each concentration/time point. Three
independent experiments were performed.
2.8.4. Eg5 and phospho-Eg5 Western Blots
Mitotic and interphase whole cell lysates (5-10 ug) were resolved in 10%
acrylamide/bis gels and electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1 %
SDS) at 100V using a Mini-PROTEAN 3 Cell System (Bio-Rad, Hercules, CA). Proteins
were transferred to PVDF membranes for 2 h at 300 V with ice cold transfer buffer (25
mM Tris, 192 mM glycine, 20 % methanol) using a Mini Trans-Blot Cell (Bio-Rad,
Hercules, CA). Membranes were blocked with Odyssey blocking buffer and incubated
overnight at 4°C with anti-Eg5 antibody (sc374212, Santa Cruz Biotechnology, Inc.,
Dallas, TX) and anti-phospho-Eg5 (T927) (ab61104, abcam, Cambridge, MA)
antibodies. The following day they were washed with 1X TBS/0.1% Tween-20 and
incubated for 1 h at room temperature with Alexa Fluor 680 and IRDye800 secondary
antibodies for 1 h at room temperature in the dark. After washing, membranes were
scanned with an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE).
Bands were quantified using Odyssey software (Li-Cor Biosciences, Lincoln, NE). Equal
protein loading was confirmed by blotting for B-actin (GT5412, GeneTex, Inc., Irvine,
CA). Normalized values were calculated by dividing Eg5 and phospho-Eg5 values over
B-actin values for each concentration/time point. Final protein levels were calculated by
dividing the normalized values from treatments over those from the control. Three
independent experiments were performed.
2.8.5. Separase and Securin Western Blots
Mitotic and interphase whole cell lysates (15-20 ug) were resolved in 8%
acrylamide/bis gels and electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1 %
SDS) at 100V using a Mini-PROTEAN 3 Cell System (Bio-Rad, Hercules, CA). The top
portions of the membranes (proteins above the 55 kDa marker) were transferred to
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nitrocellulose membranes overnight at 30 V with ice cold transfer buffer (25 mM Tris,
192 mM glycine, 10 % methanol) using a Mini Trans-Blot Cell (Bio-Rad, Hercules, CA).
The bottom portions of the membranes (proteins below the 55 kDa marker) were
transferred to nitrocellulose membranes for 2 h at 100 V with ice cold transfer buffer
(same as above but with 20% methanol). Top and bottom portions of membranes were
blocked with Odyssey blocking buffer and incubated overnight at 4°C with anti-separase
(MA1-16595, Thermo Fisher Scientific, Rockford, IL) and anti-securin (ab3305, abcam,
Cambridge, MA) antibodies. The following day they were washed with 1X TBS/0.1%
Tween-20 and incubated for 1 h at room temperature with IRDye800 secondary
antibodies for 1 h at room temperature in the dark. After washing, membranes were
scanned with an Odyssey Infrared Imaging System (Li-Cor Biosciences, Lincoln, NE).
Bands were quantified using Odyssey software (Li-Cor Biosciences, Lincoln, NE). Equal
protein loading was confirmed by blotting for B-actin (GT5412, GeneTex Inc., Irvine,
CA). Normalized values were calculated by dividing separase and securin values over Bactin values for each concentration/time point. Final protein levels were calculated by
dividing the normalized values from treatments over those from the control. Three
independent experiments were performed.

2.9. Statistics
Values were expressed as the mean ± SEM (standard error of the mean) of
triplicate experiments. The student’s t-test was used to calculate p-values to determine
the statistical significance of difference in means for each pair of concentrations. A 95%
confidence interval for the difference in means of each pair of concentrations was
constructed based on the Student’s t distribution.
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CHAPTER 3
RESULTS

3.1. Overview
Cr(VI) causes centrosome amplification, a phenotype that contributes to
chromosome instability and is commonly observed in tumors. However, how Cr(VI)
affects centrosomes is not known. Moreover, whether centrosome amplification is a
transient or permanent phenotype after Cr(VI) exposure is also unknown. Centrosomes
duplicate once and only once during a cell cycle but deregulation of the mechanisms that
control centrosome duplication can lead to centrosome amplification. A key event in
centrosome cycle control is the formation of the centrosome linkers, the G1-G2 thether
and the S-M linker. The disruption of these protein linkers controls centrosome
duplication control and contributes to the coordination of the centrosome and cell cycles.
This study has two main objectives. The first objective is to address whether
centrosome amplification after particulate Cr(VI) exposure is a permanent
phenotype. We will test this by analyzing centrosome amplification in a set of clonal cell
lines developed after repeated exposure to Cr(VI). The second objective is to analyze if
disruption of the centriole linkers is part of Cr(VI) toxicity. For this, we propose that
particulate Cr(VI) induces premature disruption of the centriole linkers by
activating Plk1. We will test this hypothesis with three specific aims: 1) Particulate
Cr(VI) induces premature disruption of the centriole linkers, 2) Particulate Cr(VI)
activates the securin-separase and Nek2/Eg5 pathways, and 3) Particulate Cr(VI)
induces Plk1 activity.
The results are presented in three parts (Figure 3.1). Part 1 shows that
centrosome amplification after Cr(VI) exposure is a permanent phenotype. Part 2
demonstrates that particulate Cr(VI) causes premature disruption of the S-M and G1-G2
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tethers. Part 3 shows that after Cr(VI) exposure the p-Plk1/Plk1 ratio increases. It also
shows that Cr(VI) decreases securin protein levels while increasing the levels of active
separase. Moreover, we also show that Cr(VI) decreases Nek2 and Eg5 protein levels
and centrosomal and microtubule localization, respectively. All three parts are presented
in detail below.

Project Objectives:

Objective 1:
Demonstrate that Particulate
Cr(VI) Causes Permanent
Centrosome Amplification

Objective 2:
Show that Particulate Cr(VI)
Induces Premature Disruption of
the Centrosome Linkers Through
Plk1 Activation

Part 1:
Particulate Cr(VI) Causes
Permanent Centrosome
Amplification
(Section 3.2)

Part 2:
Particulate Cr(VI) Induces
Premature Disruption of the
Centrosome Linkers
(Section 3.3)

Part 3:
Mechanisms of Particulate Cr(VI)Induced Disruption of the
Centrosome Linkers
(Section 3.4)

Figure 3.1. Organizational Flow Chart of the Project.
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3.2. Part 1: Particulate Cr(VI) Induces Permanent Centrosome Amplification
The first part of this study addresses whether centrosome amplification induced
by Cr(VI) is a permanent phenotypic change (Figure 3.2). For this, centrosome
amplification was analyzed in a set of clonal cell lines derived from repeated exposure to
Cr(VI). The data show that particulate Cr(VI)-induced centrosome amplification is a
permanent phenotype that persists even in the absence of Cr(VI) exposure. Centrosome
amplification appeared after the initial treatment in the 1st generation cell lines and
remained after multiple Cr(VI) treatments and throughout all clonal generations.

Part 1:
Particulate Cr(VI) Causes Permanent Centrosome Amplification
(Section 3.2)

Permanent Centrosome
Amplification Correlates with
Permanent Numerical
Chromosome Instability
(Section 3.2.2)

Centrosome Amplification
Induced by Particulate Cr(VI) is
a Permanent Phenotype
(Section 3.2.1)

Figure 3.2. Organizational Flow Chart of Part 1: Particulate Cr(VI) Causes Permanent
Centrosome Amplification.
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3.2.1. Centrosome Amplification Induced by Particulate Cr(VI) is a
Permanent Phenotype
Clonal cell lines were developed by treating WTHBF-6 cells with particulate
Cr(VI) for 24 h in three separate treatments (Wise, 2013) (Figure 3.3). After each
treatment, cells were seeded at colony forming density, cloned, expanded into cell lines
and retreated. Untreated cells were also seeded at colony forming density, cloned and
expanded three times. Overall, there were 91 control clones and 63 treated clones.
Centrosome amplification was analyzed in all clones except one treated clone (T2-1)
which was lost before the analysis. Karyotypes and numerical chromosome instability
were also analyzed (Wise, 2013). The analysis of these clones allows us to identify
permanent phenotypic changes, cellular heritability and temporal patterns of effects (i.e.
do effects happen after 1, 2 or 3 exposures) in living cells.
Figure 3.4 shows the distribution of centrosome amplification in untreated clones.
The percent of mitotic cells with centrosome amplification ranged from 0-6%, while the
parental cell line, WTHBF-6, had a background level of 3% of cells with centrosome
amplification. In contrast, in treated clones the values ranged from 0-22%. Clones with
7% or greater percent of cells with centrosome amplification were classified as having
centrosome amplification as a permanent phenotype. The threshold value was based on
the range of values observed in untreated clones (0-6%) which are likely due to effects
of the cloning process. As a result, any value above 6% was classified as centrosome
amplification. Considering all generations, 29% of Cr(VI)-treated clones have permanent
centrosome amplification (Figure 3.6A). Considering the results by generation, in the first
generation, 43% of treated clones had centrosome amplification while the second and
third generations had 44 and 21%, respectively (Figure 3.6B).
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Figure 3.3. Experimental Design of the Clonal Expansion. This figure shows the
experimental design for the clonal expansion (Wise, 2013). Cells were exposed to lead
chromate for 24 h in three separate treatments. After each treatment, cells were seeded
at colony forming density and allowed to grow for two weeks. Colonies were isolated,
expanded into cell lines and retreated. At each stage, cell lines were karyotyped and
analyzed for numerical chromosome instability as well as centrosome amplification.
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Figure 3.4. Distribution of Centrosome Amplification in Untreated Clones. This figure shows the distribution of centrosome
amplification in untreated clones. The parental cell line WTHBF-6 (Clone 6), with 3% of mitotic cells with centrosome amplification, is
shown as a reference (light blue bar). The percent of mitotic cells with centrosome amplification in untreated clones (dark blue bars)
ranged from 0 to 6%. Data represent an average of three independent experiments ± the standard error of the mean.
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Figure 3.5. Distribution of Centrosome Amplification in Treated Clones. This figure shows the distribution of the percent of mitotic
cells with centrosome amplification in treated clones. The parental cell line WTHBF-6 (Clone 6) and the untreated clone with the
highest value are shown as references (blue bars). The percent of mitotic cells with centrosome amplification in treated clones
ranged from 0 to 22% (orange bars). Data represent an average of three independent experiments ± the standard error of the mean.
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Figure 3.6. Cr(VI)-Treated Clones Exhibit Permanent Centrosome Amplification. This
figure shows the percent of treated clones with centrosome amplification. A) This panel
shows that 29% of treated clones have permanent centrosome amplification. B) This
panel shows that permanent centrosome amplification is present across all generations
of treated clones. In the first generation (G1), 43% of treated clones had centrosome
amplification while the second (G2) and third (G3) generations had 44 and 21%,
respectively. N=number of clones analyzed in each generation.
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3.2.2. Permanent Centrosome Amplification Correlates with Permanent
Numerical Chromosome Instability
Next, we compared the centrosome amplification phenotype with data on
numerical chromosome instability (CIN) for each clone (Wise, 2013). Numerical CIN can
be assessed by analyzing the karyotypes of each clone and whether it deviates from the
expected 46X,Y complement. Figure 3.7A shows that, when all generations are taken
into account, 56% of treated clones have numerical CIN compared to only 5% of control
clones. This shows that Cr(VI) treatment induces numerical CIN, which correlates with
the induction of centrosome amplification (Figure 3.7A). When analyzed by generation,
numerical CIN was present in 14% of treated clones from the 1st generation. Numerical
CIN increases with subsequent Cr(VI) treatments. The 2nd and 3rd generations had 65
and 59% of clones with numerical CIN, respectively (Figure 3.7B). When the numerical
chromosome instability phenotype is compared to the centrosome amplification
phenotype, we observe that after the first Cr(VI) treatment there is a significant increase
in centrosome amplification and a slight increase in numerical CIN. Numerical CIN
increases significantly after 2nd and 3rd treatments and correlates with the increase in
centrosome amplification in the previous generation. This is consistent with centrosome
amplification being a causative mechanism that leads to induction of numerical CIN.
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Figure 3.7. Correlation of Centrosome Amplification and Numerical Chromosome
Instability Phenotypes in Cr(VI)-treated Clones. This figure shows that an increase in
centrosome amplification correlates with an increase in numerical chromosome
instability in Cr(VI)-treated clones. A) This panel shows the correlation considering the
totality of the clones. B) This panel shows the correlation for each generation of clones.
Centrosome amplification precedes the appearance of numerical chromosome
instability.
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The above analysis shows the overall effects of repeated exposure to Cr(VI) on
clonally expanded cells. However, it does not take into account that clones are related to
each other. To analyze whether this relationship affects centrosome amplification, clones
were organized in pedigrees that show each 1st treatment clone (1st generation) with its
two subsequent clone generations (2nd and 3rd generations) (Figures 3.8-3.14).
Pedigrees also show the overlap between centrosome amplification and numerical CIN
phenotypes.
Analyzing the pedigrees, we can see that 44% of clones classified as having
permanent centrosome amplification also exhibit numerical CIN (T1-1, T1-2, T2-3, T231, T23-2, T4-2, T41-2 and T7-1). Moreover, these clones belong to families that, as a
whole, also have high percentage of clones with either numerical CIN or centrosome
amplification supporting the relatedness of these two phenotypes. All first generation
clones (i.e.: T1 through T7) had normal karyotypes (46, XY) and hence, did not have
numerical CIN. However, 43% had centrosome amplification. This is consistent with
centrosome amplification being an earlier phenotype that contributes to numerical CIN.
Clone T5 had the highest centrosome amplification value (21.7%). Interestingly,
this clone’s family was very small because only one colony survived the clonal
expansion. This colony was normal and gave rise to normal daughter clones. In contrast,
T4 and T7 had 7.7 and 7.3% centrosome amplification, respectively, and gave rise to
clones that had centrosome amplification and/or numerical CIN. Furthermore, some of
these clones had daughter clones with these phenotypes as well. Similar results are
observed between 2nd and 3rd generation clones of other families (i.e.: T2-2, T2-3, T6-1).
This indicates that the degree of centrosome amplification might determine the viability
of the cells and that at a certain level cells with amplified centrosome do not survive.
This is in agreement with centrosome amplification being a deleterious phenotype for
cells. However, at lower levels of centrosome amplification cells not only survive, but
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also develop numerical CIN. Overall, the clonal analysis suggest that centrosome
amplification and numerical CIN are persistent phenotypes after Cr(VI) exposure and
that cells that possess them have the ability to survive and give rise to daughter cells.

Figure 3.8. Pedigree of T1 Family. This figure shows individual clones of the T1 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.
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Figure 3.9. Pedigree of T2 Family. This figure shows individual clones of the T2 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.

Figure 3.10. Pedigree of T3 Family. This figure shows individual clones of the T3 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.
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Figure 3.11. Pedigree of T4 Family. This figure shows individual clones of the T4 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.

Figure 3.12. Pedigree of T5 Family. This figure shows individual clones of the T5 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.
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Figure 3.13. Pedigree of T6 Family. This figure shows individual clones of the T6 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.

Figure 3.14. Pedigree of T7 Family. This figure shows individual clones of the T7 family
with their corresponding karyotype and percent of centrosome amplification. Red letters
represent abnormal karyotypes and/or the presence of centrosome amplification.
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3.2.3. Part 1 Summary
The analysis of Cr(VI)-treated clonal cell lines shows that cells exposed to Cr(VI)
develop permanent centrosome amplification. Moreover, these cells also develop
numerical CIN. In many of the clones, centrosome amplification and numerical CIN both
occur. Given that centrosome amplification was analyzed in several independent
experiments for each clone, this further supports that these phenotypes are stable and
permanent. That is, a clone that has centrosome amplification and/or numerical CIN will
continue to have these phenotypes.

3.3. Part 2: Particulate Cr(VI) Induces Premature Disruption of the Centriole
Linkers
Given that Cr(VI) causes permanent centrosome amplification and that this
phenotype is implicated in tumorigenesis, it is important to understand the underlying
mechanisms that contribute to its appearance. The second part of this project addresses
a potential mechanism for Cr(VI)-induced centrosome amplification which involves the
premature disruption of the centriole linkers (Figure 3.15). For this, we measured two
phenotypes associated with centriole linker disruption in Cr(VI)-treated cells: centriole
disengagement and centrosome separation. The data show that particulate Cr(VI)
induces premature centriole disengagement and centrosome separation in interphase
cells, consistent with a disruption of the centriole linkers and/or the mechanisms that
regulate them.
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Part 2:
Particulate Cr(VI)
Induces Premature
Disruption of the
Centriole Linkers
(Section 3.3)

Particulate Cr(VI)
Induces
Supernumerary
Centrioles
(Section 3.3.1)

Particulate Cr(VI)
Induces Premature
Centriole
Disengagement
(Section 3.3.2)

Particulate Cr(VI)
Induces Premature
Centrosome Separation
(Section 3.3.3)

Figure 3.15. Organizational Flow Chart of Part 2: Particulate Cr(VI) Induces Premature
Disruption of the Centriole Linkers.
3.3.1. Particulate Cr(VI) Induces Supernumerary Centrioles
As shown in Part 1, Cr(VI) causes centrosome amplification and numerical CIN.
In order to study the mechanisms underlying centrosome amplification, we exposed
human lung cells for 24, 72 and 120 h to 0, 0.1, 0.15 and 0.2 ug/cm2 zinc chromate, a
particulate form of Cr(VI). These concentrations have been previously shown to induce
centrosome amplification after chronic exposures (i.e.: >24 h) (Holmes et al., 2010).
Figure 3.16A shows the centrosome amplification data from Holmes et al. (2010)
arranged in a side-by-side comparison of interphase versus mitotic cells. This figure
shows that after 24 h exposure human lung cells exposed to zinc chromate do not show
centrosome amplification. In contrast, chronic exposure (i.e.: 72 and 120 h) to zinc
chromate caused a statistically significant time- and concentration-dependent increase in
centrosome amplification in both interphase and mitotic cells (p<0.05). In interphase
cells, a 24 h exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate induced 2.9, 2.2 and
2.6 percent of cells with centrosome amplification, respectively; while after 120 h
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exposure the same concentrations induced 13.9, 18 and 21.3 percent of cells with
centrosome amplification. The same pattern was observed in mitotic cells. After 24 h
exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate, there were 1, 1 and 1 percent of
cells with centrosome amplification, respectively; while after 120 h exposure the same
concentrations induced 21, 33 and 46 percent of cells with centrosome amplification.
In Cr(VI)-treated clones we observed a correlation between centrosome
amplification and numerical CIN. However, Holmes et al. (2010) did not show the
correlations between the centrosome amplification and numerical CIN phenotypes in
cells exposed to Cr(VI) for 24, 72 and 120 h. The correlations for their data are shown in
Figure 3.16B. Chromosome numbers were analyzed in solid stained metaphases after
24, 72 and 120 h exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate. The data show
that after 24 h exposure there is no increase in the percent of cells with numerical CIN,
while after 72 and 120 h there is a statistically significant time- and dose-dependent
increase in the percent of cells with numerical CIN (p<0.05). A 24 h exposure to 0.1,
0.15 and 0.2 ug/cm2 zinc chromate induced 13, 13, 13.7 and 14.3 percent of cells with
numerical CIN, respectively, while after 120 h exposure, the same concentrations
induced 28, 40.3 and 44.3 percent of cells with numerical CIN.
Most importantly, the time- and concentration-dependent increase observed in
numerical CIN correlated with the time- and concentration-dependent increase in
centrosome amplification in mitotic cells (Figure 3.16B). We used mitotic cells as a
comparison because numerical CIN was assessed in metaphases, which correspond to
a mitotic phase. After 24 h exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate, there is
no increase in numerical CIN or centrosome amplification, while after 72 and 120 h
exposure to the same concentrations, both numerical CIN and centrosome amplification
increase proportionally with time and concentration.
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Figure 3.16. Chronic Exposure to Cr(VI) Induces Numerical CIN and Centrosome
Amplification in Human Lung Cells. This figure shows that chronic exposure to zinc
chromate induces a time- and concentration-dependent increase in numerical CIN and
centrosome amplification. A) Percent of cells with centrosome amplification in interphase
and mitotic cells. B) Percent of metaphases with numerical CIN and its correlation with
percent of cells with centrosome amplification in mitosis. Both phenotypes show a similar
increase. *Statistically different from the control (p<0.05). Data represent an average of
three independent experiments ± the standard error of the mean.
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Centrosome amplification can be caused by different mechanisms which include
multiple

rounds

of

centrosome

duplication
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one

cell
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centriole

disengagement, formation of acentriolar centrosomes and failure of cytokinesis
(Fukasawa, 2005). The analysis of centrioles, the microtubule-based structures within
each centrosome, can be used to distinguish some of these phenotypes (Fukasawa,
2005). To gain a better understanding of Cr(VI)-induced centrosome amplification, we
used the centriole marker centrin to stain and count centrioles after Cr(VI) treatment
Figure 3.17A shows the effects of Cr(VI) on centriole numbers in interphase cells.
In interphase, normal G1 phase cells have two centrioles while normal S and G2 phase
cells have four centrioles. Chronic exposure to zinc chromate induced a time-dependent
increase in the percent of cells that had supernumerary centrioles in both interphase and
mitotic cells. In interphase cells, the percent of G1 cells (i.e.: with two centrioles)
remained constant with increased exposure time and concentration. For example, after a
24 h exposure to 0.2 ug/cm2 zinc chromate the percent of cells with 2 centrioles was
54%, while after 120 h exposure, it was 52%. The percent of cells with three centrioles
also remained constant with treatment and increased exposure time. After 24 h
exposure to 0.2 ug/cm2 zinc chromate there was 1% of interphase cells with 3 centrioles,
while after 120 h the percent of cells was 4%.
In contrast, after exposure to zinc chromate there was a time-dependent
decrease in the percent of cells with 4 centrioles (i.e.: S or G2 phase cells). After 24 h
exposure to 0.2 ug/cm2 zinc chromate the percent of cells with 4 centrioles was 45%,
while after 120 h exposure, it was 36%. This decrease was not statistically significant but
shows a clear trend. In parallel, the percent of cells with supernumerary centrioles also
increased with exposure time and concentration. After 24 h exposure to 0.2 ug/cm 2 zinc
chromate the percent of cells greater than 4 centrioles was 1%, while after 120 h
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exposure, it was 8%. This increase was not statistically significant but also shows a clear
trend.
Figure 3.17B shows the effects of Cr(VI) exposure on centriole number in mitotic
cells. Normal mitotic cells have four centrioles at any mitotic phase. In mitotic cells, there
was a statistically significant decrease (p<0.05) in the percent of cells with four
centrioles. After 24 h exposure to 0.2 ug/cm2 zinc chromate there were 94% of mitotic
cells with 4 centrioles, while after 120 h exposure, the percent of cells decreased to
67%. In parallel, there was a statistically significant increase (p<0.05) in the percent of
mitotic cells with supernumerary centrioles. After 24 h exposure to 0.2 ug/cm2 zinc
chromate, the percent of mitotic cells with supernumerary centrioles was 6%, while after
120 h exposure the percent of cells increased to 30%. No changes were observed in the
percent of mitotic cells with 3 centrioles. After 24 h exposure to 0.2 ug/cm 2 zinc chromate
there were 0% interphase cells with 3 centrioles, while after 120 h the percent of cells
was 3%.
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Figure 3.17. Chronic Exposure to Cr(VI) Induces Supernumerary Centrioles in
Interphase and Mitotic Cells. This figure shows that Cr(VI) exposure induces an increase
in centriole numbers in interphase and mitotic cells. A) Interphase cells exposed to
Cr(VI) show a time-dependent decrease in the percent of cells with 4 centrioles and an
increase in the percent of cells with greater than four centrioles. B) Mitotic cells exposed
to Cr(VI) show a time-dependent decrease in the percent of cells with 4 centrioles and
an increase in the percent of cells with greater than 4 centrioles. a, Cells with
supernumerary centrioles are statistically different from the control (p<0.05); b, Cells with
normal number of centrioles are statistically different from the control (p<0.05). Data
represent an average of three independent experiments ± the standard error of the
mean.
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3.3.2. Particulate Cr(VI) Induces Premature Centriole Disengagement
When cells divide, each daughter cell inherits one centrosome with two
centrioles. Each centriole will duplicate once during the following S phase in order to
maintain a correct number of centrioles for the future two daughter cells. Centriole
duplication is regulated through the engagement of the inherited centrioles. While
engaged, centriole duplication is inhibited. However, when centrioles disengage,
centrioles can undergo duplication. The increase in centriole numbers observed in cells
exposed to Cr(VI) suggests that some Cr(VI)-treated cells are undergoing multiple
rounds of centriole duplication. Given that centriole disengagement is the licensing factor
for centriole duplication, we analyzed centriole disengagement after Cr(VI) exposure.
Normal centriole disengagement usually occurs as cells exit mitosis or very early
in G1 phase (Agircan et al., 2014). Hence, we hypothesized that Cr(VI)-treated cells
might exhibit premature centriole disengagement (i.e.: occurring in S or G2 phase or in
mitosis before anaphase). This could result in centrosome amplification because
disengaged centrioles can undergo re-duplication thus increasing centriole and
centrosome numbers (Tsou and Stearns, 2006a). Since Cr(VI) exposure induces
increases

in

disengagement

both

centriole

seems

a

and

centrosome

numbers,

feasible

mechanism

for

premature

Cr(VI)-induced

centriole

centrosome

amplification.
To quantify centriole disengagement we analyzed the ratios of centriolar proteins
centrin and C-Nap1. Centrin is a core component of centrioles while C-Nap1 localizes to
the free proximal end of centrioles. When two centrioles are engaged, they have two
centrin foci (one from each centriole) and one C-Nap1 foci at the free proximal end of the
mother centriole (Tsou and Stearns, 2006b). Thus, engaged centrioles have a 2:1
centrin:C-Nap1 foci ratio. By contrast, disengaged centrioles have two free proximal
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ends, one from the mother centriole and one from the now disengaged daughter
centriole creating a 1:1 centrin:C-Nap1 foci ratio (Figure 3.18).

Figure 3.18. Centriole Disengagement and Centrin/C-Nap1 Ratios. This figure shows
schematics and representative images of cells with engaged and disengaged centrioles
and their corresponding centrin/C-Nap1 ratio. Pink circles represents centrosomes, blue
cylinders represent centrioles with centrin shown in green, while red circles represent CNap foci. G1 cells with engaged centrioles have one centrosome with 2 centrioles and
one C-Nap1 focus, while G1 cells with disengaged centrioles have two centrosomes,
each with one centriole and one C-Nap1 focus. Cells in S, G2 or mitosis with engaged
centrioles have two centrosomes, each with two centrioles and one C-Nap1 focus, while
cells with disengaged centrioles have four centrosomes, each with an individual centriole
and C-Nap1 focus.

Figure 3.19 shows the effects of Cr(VI) on centriole disengagement in G1, S/G2
and mitotic cells. For this analysis we quantified centrin/C-Nap1 ratios in interphase and
mitotic cells focusing the analysis in cells that have a normal number of centrioles.
Normal G1 cells have two centrioles and normal S, G2 and mitotic cells have four
centrioles. Cells with supernumerary centrioles display centrosomes with more than 2
centrioles as well as centriolar defects such as centrosomes without centrioles, which
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make centrin/C-Nap1 ratios very difficult to determine. Moreover, because centriole
numbers are abnormal it is impossible to determine the original centrioles which
underwent disengagement. In cells with normal number of centrioles, these limitations
are not present.
First, we analyzed centriole disengagement in interphase cells with two centrioles
which are considered G1 cells. Figure 3.19A shows that Cr(VI) exposure induces a timedependent increase in centriole disengagement in G1 cells. This increase was not found
to be statistically significant but the data show a strong trend. After 24 h exposure to 0.1,
0.15 and 0.2 ug/cm2 zinc chromate, centriole disengagement was present in 49, 45 and
37% of interphase cells with two centrioles, respectively; while after 120 h exposure the
percent of cells with centriole disengagement was 72, 75 and 88%, respectively. It is
worth mentioning that centriole disengagement can occur in early G1 and as such this
increase observed after Cr(VI) exposure cannot be considered abnormal.
Next, we analyzed centriole disengagement in interphase cells with 4 centrioles,
which can either be S or G2 phase cells. Figure 3.19B shows that in this population of
cells Cr(VI) induced a statistically significant time- and concentration-dependent increase
in centriole disengagement (p<0.05). After 24 h exposure to 0.1, 0.15 and 0.2 ug/cm 2
zinc chromate, centriole disengagement was present in 1, 5 and 4% of interphase cells
with 4 centrioles, respectively; while after 120 h exposure the percent of cells with
centriole disengagement was 25, 40 and 51%, respectively. This increase in
disengagement is abnormal and premature with respect to the following cell cycle, which
is when centrioles from previous cycle should disengage. Thus, the data show that
chronic exposure to Cr(VI) causes premature centriole disengagement in interphase
cells.
Last, we analyzed centriole disengagement in mitotic cells whose normal
centriole number is four. Figure 3.19C shows that in normal mitotic cells Cr(VI) does not
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cause centriole disengagement. After 24 h exposure to 0.2 ug/cm2 zinc chromate,
centriole disengagement was not present in any mitotic cells, while after 120 h exposure
the percent of mitotic cells with centriole disengagement was 3%. This slight increase
was not statistically significant.

Figure 3.19. Chronic Exposure to Cr(VI) Induces Premature Centriole Disengagement in
Interphase Cells with 4 Centrioles. This figure shows that chronic exposure to zinc
chromate induces premature centriole disengagement in S/G2 cells. A) Centriole
disengagement in G1 cells (i.e.: interphase cells with 2 centrioles) B) Centriole
disengagement in S/G2 cells (i.e.: interphase cells with 4 centrioles) C) Centriole
disengagement in mitotic cells. *Statistically significant difference from the control
(p<0.05). Data represent an average of three independent experiments ± the standard
error of the mean.
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For the centriole disengagement analysis, we made the assumption that cells
with two centrioles were in G1 phase, and that cells with four centrioles were in either S
or G2 phase. To support the notion that Cr(VI) causes premature centriole
disengagement in S/G2 cells we stained cells with cyclin D1, a G1 phase cell cycle
marker. We quantified centrioles in cyclin D1-positive cells and found that indeed, cells
with two centrioles are in G1 phase (Figure 3.20). Moreover, exposure to 0.2 ug/cm2 zinc
chromate for 24 and 72 h did not change the percent of cyclin D1-positive cells with two
centrioles. There was a slight and statistically significant increase in the percent of cells
in G1 phase with four centrioles at 120 h, but this small increase (6%) cannot account for
all of the centriole disengagement observed in cells with four centrioles after 120 h
exposure (Figure 3.19B). This data confirms that interphase cells with two centrioles are
in G1 phase and interphase cells with four centrioles are not, and as such, they must be
in S or G2 phase, and supports that premature centriole disengagement after Cr(VI)
exposure is in S/G2 cells as shown in Figure 3.19B.
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Figure 3.20. Number of Centrioles in G1 cells After Cr(VI) Exposure. This figure shows
the number of centrioles in cells stained with cyclin D1, a G1 phase marker. The majority
of cyclin D1 positive cells have two centrioles. There is a small increase in the percent of
G1 cells that have four centrioles after 120 h exposure to Cr(VI). *Statistically significant
difference from the control (p<0.05). Data represent an average of three independent
experiments ± the standard error of the mean.

3.3.3. Particulate Cr(VI) Induces Premature Centrosome Separation
Duplicated centrosomes formed in S phase are normally held together by the G1G2 tether. This linker is severed at the G2/M transition and allows centrosomes to
separate in prophase so that they can be positioned in a bipolar fashion. Interestingly,
depletion of G1-G2 tether proteins by siRNA caused increased centriole disengagement
when cells were exposed to a DNA damaging agent (Conroy et al., 2012). This suggests
that the G1-G2 tether may be involved in protecting centriole engagement. Since Cr(VI)
is a strong DNA damaging agent and causes centriole disengagement, we hypothesized
that Cr(VI) exposure might also disrupt this linker. Hence, we measured centrosome
separation in interphase cells under the premise that if this linker is severed,
centrosomes would prematurely separate in interphase (Mayor et al. 2000; Faragher and
Fry, 2003; Bahe et al., 2005; Mardin and Schiebel, 2012). Using γ-tubulin as a marker
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for centrosomes, we measured the distance between pairs of centrosomes.
Centrosomes were classified as separated if the distance between them was greater
than 2 um (Mayor et al., 2000) (Figure 3.21).

Figure 3.21. Representative Images of Centrosome Separation Analysis. This figure
shows an interphase cell with centrosomes that are still attached to each other (left) and
an interphase cell with separated centrosomes (right). Blue staining corresponds to DNA
and orange staining to centrosomes. Green lines are used to measure the distance
between each pair of centrosomes. Centrosomes with distances >2 um are considered
separated.

Figure 3.22 shows that chronic exposure to Cr(VI) induced a statistically
significant (p<0.05) time- and dose-dependent increase in the percent of interphase cells
with separated centrosomes. After 24 h exposure to 0.1, 0.15 and 0.2 ug/cm 2 zinc
chromate the percent of interphase cells with separated centrosomes was 15, 15 and
13%, while after 120 h exposure the percent of cells increased to 30, 33 and 36%,
respectively. Given that the centrosome separation analysis was done in interphase cells
and that centrosomes normally separate in prophase of mitosis, centrosome separation
induced by Cr(VI) is premature.
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Figure 3.22. Chronic Exposure to Cr(VI) Induces Premature Centrosome Separation.
This figure shows that chronic exposure to zinc chromate induces a time- and
concentration-dependent increase in premature centrosome separation in interphase
cells. *Statistically significant difference from the control (p<0.05). Data represent an
average of three independent experiments ± the standard error of the mean.

Moreover, this time- and dose-dependent increase in premature centrosome separation
in interphase cells correlates with the time- and dose-dependent increase in premature
centriole disengagement observed in S/G2 cells (Figure 3.23A). More importantly, both
premature centriole disengagement and premature centrosome separation also correlate
with the increased centrosome separation observed in interphase cells after Cr(VI)
exposure (Figure 3.23B and 3.23C).
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Figure 3.23. Correlations between Centrosome Separation, Centriole Disengagement,
and Centrosome Amplification. This figure shows that premature centriole
disengagement and premature centrosome separation correlate with each other as well
as with centrosome amplification in interphase cells. After chronic exposure to Cr(VI), all
phenotypes show a similar increase. A) Correlation between premature centriole
disengagement (left y axis) and premature centrosome separation (right y axis). B)
Correlation between premature centriole disengagement (left y axis) and centrosome
amplification (right y axis). C) Correlation between premature centrosome separation
(left y axis) and centrosome amplification (right y axis). Data represent an average of
three independent experiments ± the standard error of the mean.
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3.3.4. Part 2 Summary
In Part 2 we have begun to elucidate some of the mechanism that may underlie
the centrosome amplification observed after Cr(VI) exposure. The analysis of centrioles
and centrosomes in interphase and mitotic cells after Cr(VI) exposure shows that chronic
exposure to Cr(VI) causes a slight increase in supernumerary centrioles in interphase
cells and a significant increase in supernumerary centrioles in mitotic cells. This
suggests that centriole overduplication might play a role in Cr(VI)-induced centrosome
amplification. The licensing step for centriole duplication is centriole disengagement.
Consistent with the increase in supernumerary centrioles, chronic exposure to Cr(VI)
induces a time- and dose- dependent increase in premature centriole disengagement in
interphase cells during S/G2 phase. In addition, premature centrosome separation is
also observed in interphase cells exposed chronically to Cr(VI). Both centriole
engagement and centrosome attachment are possible due to protein linkers that link
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centrioles and centrosomes together. Our data suggest that Cr(VI) is affecting these
linkers proteins or their regulation causing the linkers to disrupt prematurely.

3.4. Part 3: Mechanisms of Particulate Cr(VI)-Induced Disruption of the Centriole
Linkers
The formation and disruption of the centriole linkers are important aspects of
centrosome cycle regulation. As such, they are tightly regulated by different proteins. In
Part 3, we explore the effects of chronic exposure to particulate Cr(VI) on proteins
involved in linker disruption. We analyzed protein levels and localization of proteins
involved in centriole disengagement and centrosome separation, as well as their
upstream regulator, Plk1 (Figure 3.24). The data show that particulate Cr(VI) increases
the ratio of p-Plk1/Plk1. The separase-securin pathway that causes centriole
disengagement is also affected by Cr(VI) through increased levels of active separase
and decreased levels of securin, which are consistent with the observed centriole
disengagement. The Nek2-Eg5 pathway involved in centrosome separation has
decreased protein levels and decreased centrosome and microtubule localization after
Cr(VI) exposure, suggesting that parallel mechanisms separate centrosomes after Cr(VI)
exposure.
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Part 3:
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Particulate Cr(VI)Induced Disruption of
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(Section 3.4)
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Figure 3.24. Organizational Flow Chart of Part 3: Mechanisms of Particulate Cr(VI)Induced Disruption of the Centriole Linkers.
3.4.1. Particulate Cr(VI) Increases the p-Plk1/Plk1 Ratio
The disruption of the centriole linkers is a key event in the centrosome cycle. As
such, it is tightly regulated by numerous proteins. Upstream of the regulation cascade is
Polo-like kinase 1 (Plk1), a serine-threonine kinase involved in many aspects of the cell
and centrosome cycles. Plk1 is activated by phosphorylation of its catalytic loop in
threonine 210 (T210) during late G2 phase and remains active throughout mitosis.
Because of its pivotal role in centrosome linker disruption and given that Cr(VI)
causes premature centriole disengagement and centrosome separation, we investigated
the effects of Cr(VI) on the levels of active Plk1. Active Plk1 (p-Plk1) is phosphorylated
on T210 and can be recognized by multiple commercially available antibodies. Hence,
quantitative western blotting can be used to measure the levels of active protein. Also,
because the overall activity of Plk1 in a cell is determined by the balance between its
active and inactive states, we also measured levels of inactive Plk1. Furthermore, since
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premature centriole disengagement and premature centrosome separation after Cr(VI)
exposure were observed in interphase, we separated interphase cells from mitotic cells
by doing a mitotic shake-off. This allowed us to analyze p-Plk1 and Plk1 protein levels in
interphase and mitotic cells separately.
Figure 3.25A shows representative images of p-Plk1 and Plk1 western blots after
24 and 120 h exposure to 0.2 ug/cm2 zinc chromate. The data show that in interphase
cells (Figure 3.25B), Plk1 levels decrease significantly after Cr(VI) exposure (p<0.05).
After 24 h exposure to 0.2 ug/cm2 zinc chromate, Plk1 protein levels were 0.78 relative
to control (set as 1), while after 72 and 120 h exposures, Plk1 protein levels were 0.33
and 0.32 relative to control. In contrast, p-Plk1 levels remain constant after Cr(VI)
exposure. After 24 h exposure to 0.2 ug/cm2 zinc chromate, p-Plk1 protein levels were
0.86 relative to control (set as 1), while after 72 and 120 h exposures, p-Plk1 protein
levels were 0.77 and 0.90 relative to control.
In mitotic cells, both p-Plk1 and Plk1 decreased significantly after Cr(VI)
exposure (p <0.05) (Figure 3.25C). Exposure to 0.2 ug/cm2 zinc chromate for 24, 72 and
120 h decreased Plk1 levels to 0.97, 0.47 and 0.17 relative to control value, respectively.
p-Plk1 levels also significantly decreased after Cr(VI) exposure (p<0.05). After 24, 72
and 120 h exposure to 0.2 ug/cm2 zinc chromate, Plk1 levels were to 0.87, 0.82 and 0.52
relative to control, respectively.
Overall kinase activity in cells depends on a fine balance between active versus
inactive forms (Domingo-Sananes et al., 2011). Hence, we calculated ratios of p-Plk1
versus Plk1 after Cr(VI) exposure (Figure 3.25D). A p-Plk1/Plk1 ratio greater than 1
indicates the balance is tilted towards an excess of active Plk1, while a ratio lower than 1
indicates the balance is tilted towards an excess of inactive Plk1. The data show that
after chronic exposure to Cr(VI) the p-Plk1/Plk1 ratio is greatly increased. In interphase
cells, after 24, 72 and 120 h exposure to 0.2 ug/cm2 zinc chromate the p-Plk1/Plk1 ratio
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increased to 1.2, 2.8 and 5.4, respectively. In mitotic cells, a similar increase was
observed. After 24, 72 and 120 h exposure to 0.2 ug/cm2 zinc chromate the p-Plk1/Plk1
ratios were 1, 2 and 3.9, respectively. The data indicate that chronic exposure to Cr(VI)
increases p-Plk1 levels 4-6 fold over inactive Plk1. This suggest that Plk1 activity is
increased after Cr(VI) treatment.
Figure 3.25. Cr(VI) Exposure Increases the p-Plk1/Plk1 Ratio. This figure shows that
chronic exposure to Cr(VI) causes an overall increase in p-Plk1 levels. A)
Representative images of western blots for p-Plk1 (red) and Plk1 (green), the merged
images and loading control (B-actin, green). B) Protein levels of Plk1 (dark gray bars)
and p-Plk1 (light grey bars) in interphase cells after Cr(VI) exposure. C) Protein levels of
Plk1 (dark gray bars) and p-Plk1 (light grey bars) in mitotic cells after Cr(VI) exposure.
D) Ratios of p-Plk1/Plk1 protein levels in interphase (dark grey bars) and mitotic cells
(light grey bars). *Statistically significant difference from the control (p<0.05). Data
represent an average of three independent experiments ± the standard error of the
mean.
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Figure 3.25. Continued.
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Figure 3.25. Continued.
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3.4.2. Mechanisms of Centriole Disengagement: Particulate Cr(VI) Increases
Active Separase while Decreasing Securin Protein Levels
Centriole disengagement is dependent on the activity of the protease separase
(Figure 3.26). Separase activity is inhibited by securin, its binding partner. Plk1 activation
activates the anaphase promoting complex/cyclosome (APC/C) which ubiquitinates
proteins targeting them for degradation. One of the APC/C’s main targets is securin.
Upon securin degradation, separase becomes active and cleaves the proteins cohesin
and pericentrin B involved in centriole engagement. In normal cells, this happens at the
end of mitosis or early G1. Since our data show that chronic exposure to Cr(VI) causes
premature centriole disengagement in interphase cells and that p-Plk1 levels are
increased after Cr(VI) exposure, we analyzed separase and securin levels. For this, we
used western blots to measure separase and securin protein levels in interphase cells.
Because premature centriole disengagement is observed in interphase, our analysis was
limited to interphase cells.
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Figure 3.27A shows representative images of separase and securin western
blots. For separase analysis, we quantified two separate bands. The 220 kDa band
corresponding to full-length separase, which is the inactive form bound to securin. We
also quantified the 65 kDa band, which is a product of separase autocleavage upon its
activation following securin degradation. Quantifying these bands allows us to indirectly
assess separase activity after Cr(VI) exposure. Figure 3.27B shows the effects of Cr(VI)
on separase protein levels. Full-length separase levels significantly decreased (p<0.05)
after chronic exposure to Cr(VI). After 24 h exposure to 0.2 ug/cm 2 zinc chromate
separase protein levels was 1.12 relative to control, while after 72 and 120 h exposures
protein levels decreased to 0.44 and 0.07 relative to control, respectively. In contrast,
protein levels of cleaved separase significantly increased after chronic Cr(VI) treatment
(p<0.05). At 24 h exposure to 0.2 ug/cm2 zinc chromate, cleaved separase levels were
1.2 relative to control, while after 120 h exposure protein levels increased to 1.6 relative
to control.
Figure 3.27B also shows the effects of Cr(VI) on securin protein levels. Securin
protein levels significantly decreased after Cr(VI) treatment (p<0.05). After 24 h
exposure to 0.2 ug/cm2 zinc chromate, securin protein levels were 0.89 relative to control
while after 72 and 120 h exposures, protein levels were 0.36 and 0.17 relative to control,
respectively.
Overall, our data show that chronic exposure to particulate Cr(VI) decreases
securin protein levels. Consistent with this decrease, protein levels of full-length
separase (inactive form) also decrease after Cr(VI) exposure. Because protein levels of
cleaved separase (active form) increase after Cr(VI) treatment, the decrease in fulllength separase can be partially attributed to separase activation and autocleavage after
securin degradation.
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Figure 3.26. Centriole Disengagement Mechanism. This figure shows the molecular
mechanism underlying centriole disengagement. 1) Plk1 activation in mitosis causes a
signaling cascade that acts upon many substrates, including securin. 2) Securin is
degraded by the proteasome during anaphase. 3) Securin degradation frees separase
which becomes active. 4) Separase activation leads to auto-cleavage. 5) Active
separase acts on proteins forming the S-M linker leading to its proteolysis. 6) S-M linker
proteolysis causes centriole disengagement in late mitosis/early G1.
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Figure 3.27. Cr(VI) Induces an Increase in Active Separase and Decreases Securin.
This figure shows that chronic exposure to particulate Cr(VI) decreases securin and fulllength separase protein levels while increasing levels of autocleaved separase. A)
Representative images of western blots showing bands corresponding to full-length
separase, cleaved separase, securing and B-actin (loading control). B) Quantification of
full-length separase (light black bars), cleaved separase (dark grey bars) and securin
(light grey bars). *Statistically significant difference from the control (p<0.05). Data
represent an average of three independent experiments ± the standard error of the
mean.
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3.4.3. Mechanisms of Centrosome Separation: Particulate Cr(VI) Decreases
Protein Levels and Localization of Nek2 and Eg5
Given that Cr(VI) causes premature centrosome separation, we examined the
effects of Cr(VI) on proteins that control centrosome separation. As with centriole
disengagement, centrosome separation is also regulated via Plk1 activation and the
Nek2A-Mst1-PP1 complex (Figure 3.28). Nek2A is a kinase that can undergo
autophosphorylation. However, phosphate groups on Nek2A are removed by the
phosphatase PP1, keeping the complex inactive. Upon Plk1 activation, Plk1
phosphorylates Mst2 inducing a conformational change that prevents binding of PP1. As
a result, PP1 can no longer dephosphorylate Nek2A and Nek2A remains
phosphorylated, increasing its kinase activity. Kinase activity reaches a peak during the
G2/M transition and Nek2A phosphorylates linker proteins C-Nap1, Rootletin and
LRRC45 leading to their removal and releasing centrosomes from each other so that
they can separate in prophase.
To study the effects of Cr(VI) on Nek2A, we analyzed protein levels with western
blots as well as its centrosomal localization using immunofluorescence. Figure 3.29A
shows representative images of Nek2 western blots. Nek2 exists in isoforms A and B
with 48 and 46 kDa, respectively. Because of their molecular weight difference, these
isoforms are separated during electrophoresis and appear as two distinct bands on
blots. We only quantified the Nek2A band since this is the isoform involved in
centrosome separation. Figure 3.29B shows that chronic exposure to particulate Cr(VI)
causes a statistically significant decrease in Nek2A protein levels (p<0.05). After 24 h
exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate, Nek2A protein levels were 97, 93
and 76 percent of control, respectively; while after 120 h exposure protein levels
decreased to 57, 69 and 23 percent of control, respectively.
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Since Nek2A activity is required at the centrosome, we also analyzed its
centrosomal localization after Cr(VI) exposure. Figure 3.30A shows representative
images of cells with Nek2 localized at the centrosomes. Currently, isoform-specific
antibodies for Nek2 are not available so we could not narrow the localization analysis to
solely Nek2A. Figure 3.30B shows that chronic exposure to Cr(VI) decreases
centrosomal localization of Nek2 (p<0.05). After 24 h exposure to 0.1, 0.15 and 0.2
ug/cm2 zinc chromate, the percent of cells with Nek2 localized to the centrosomes was
97, 93 and 76 percent, respectively; while after 120 h exposure the percent of cells with
Nek2 localized to the centrosome was 28, 11 and 10 percent of control, respectively. In
normal cells, Nek2 activity and centrosomal localization are required in late G2 phase.
Hence, we also analyzed Nek2 localization in G2 phase cells using cyclin B1 as a G2
phase marker (Figure 3.31A). Interestingly, chronic exposure to Cr(VI) did not change
centrosomal localization of Nek (Figure 3.31B). After 24, 72 and 120 h exposure to 0.2
ug/cm zinc chromate the percent of G2 phase cells with centrosomal localization of Nek2
was 95, 93 and 94%, respectively.
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Figure 3.28. Centrosome Separation Mechanism. This figure shows the mechanism of
centrosome separation. 1) The G1-G2 tether holds centrosomes together. 2) The
kinases Nek2 and Mst2 form a complex with phosphatase PP1. Mst2 is phosphorylated
by active Plk1 at the end of the G2/M transtition. 3) Mst2 phosphorylation induces a
conformational change that prevents PP1 binding. This allows Nek2 to become active
and autophosphorylate. 4) Active Nek2 phosphorylates G1-G2 tether proteins leading to
their removal from centrosomes. 5) In prophase, the absence of the G1-G2 tether allows
for centrosome separation. This is achieved through microtubule movements produced
by the motor protein Eg5. 6) Plk1 phosphorylation contributes to Eg5 activation.

104

Nek2A Total Protein Level
(Percent of Control)

120
100
80

*

*

40
20
0

0.2

0.15

0.1

0

72 h

0.2

0.15

0.1

0

0.2

0.15

0.1

0

24 h
B)

*

*

60

120 h

Zinc Chromate Concentration (ug/cm2)

Figure 3.29. Cr(VI) Decreases Nek2A Protein Levels. This figure shows that chronic
exposure to Cr(VI) decreases Nek2A protein levels. A) Representative images of Nek2
western blots. The two bands correspond to two isoforms: Nek2A and Nek2B. Nek2A is
the top band. B) Total protein levels of Nek2A after Cr(VI) exposure. *Statistically
significant difference from the control (p<0.05). Data represent an average of two
independent experiments ± the standard error of the mean.
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Figure 3.30. Nek2 Centrosomal Localization in Interphase Cells after Cr(VI) Exposure.
This figure shows that chronic exposure to Cr(VI) decreases Nek2A centrosomal
localization in interphase cells. A) Representative images of an interphase cell with Nek2
localization to the centrosomes. Blue, green and red represent DNA, Nek2, and
centrosomes, respectively. B) Nek2 centrosomal localization after Cr(VI) exposure.
*Statistically significant difference from the control (p<0.05). Data represent an average
of three independent experiments ± the standard error of the mean.
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Figure 3.31. Nek2 Centrosomal Localization in G2 Phase Cells after Cr(VI) Exposure.
This figure shows that chronic exposure to Cr(VI) does not affect Nek2 centrosomal
localization in G2 phase cells. A) Representative images of a G2 cell with Nek2
localization to centrosomes. Blue, red, pink and green represent DNA, cyclin D1,
centrosomes and Nek2, respectively. B) Nek2 centrosomal localization in G2 phase cells
after Cr(VI) exposure. Data represent an average of two independent experiments ± the
standard error of the mean.
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Cr(VI) exposure decreases Nek2 protein levels and localization which are in
disagreement with the premature centrosome separation observed in interphase cells.
However, lack of Nek2 can be compensated by Eg5, the motor protein responsible for
microtubule movements involved in centrosome separation (Mardin et al., 2010).
Consequently, we analyzed protein levels of Eg5 in interphase cells after Cr(VI)
exposure. Binding of Eg5 to microtubules is dependent on Cdk1-dependent
phosphorylation on threonine 927 (Blangy et al., 1995). Since there are antibodies that
recognize this phosphorlyated site, we also measured phosphorylated Eg5 (p-Eg5)
protein levels. Because Eg5 activity is restricted to microtubules, we also analyzed the
effects of Cr(VI) on its microtubule localization.
Figure 3.32A shows representative images of western blots for Eg5 and p-Eg5,
the merged images and B-actin which was used as a loading control. Western blots
were performed with interphase cell lysates, following the same procedures to remove
mitotic cells used for the Plk1 and p-Plk1 western blots. Chronic exposure to Cr(VI)
significantly decreased Eg5 and p-Eg5 protein levels (p<0.05) (Figure 3.32B). After 24,
72 and 120 h exposure to 0.2 ug/cm2 zinc chromate, Eg5 protein levels were 0.89, 0.26
and 0.11 relative to control, respectively; while p-Eg5 levels were 1.25, 0.24 and 0.22,
respectively. Microtubule localization of Eg5 in interphase cells was also significantly
decreased after chronic exposure to Cr(VI) treatment (p<0.05) (Figure 3.33B). Figure
3.33A shows representative images of cells with and without Eg5 localized to
microtubules. After exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate, there were 64,
62 and 69% of cells with Eg5 localized to microtubules, while after 120 h exposure there
were 26, 15 and 8% of cells, respectively.
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Figure 3.32. Eg5 Protein Levels in Interphase Cells after Cr(VI) Exposure. This figure
shows that chronic exposure to Cr(VI) decreases protein levels of Eg5 and p-Eg5 (pEg5). A) Representative images of Eg5 western blots showing p-Eg5 in red, Eg5 in
green, the merged images and B-actin as a loading control. B) Eg5 and p-Eg5 protein
levels in interphase cells decrease after Cr(VI) exposure. *Statistically significant
difference from the control (p<0.05). Data represent an average of three independent
experiments ± the standard error of the mean.
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Figure 3.33. Eg5 Localization to Microtubules in Interphase Cells after Cr(VI) Exposure.
This figure shows that chronic exposure to Cr(VI) decreases Eg5 localization to
microtubules in interphase cells. A) Representative images of cells with and without Eg5
localization to microtubules. Blue, green and red represent DNA, microtubules and Eg5,
respectively. B) Eg5 localization to microtubules in interphase cells decreasaes after
Cr(VI) exposure. *Statistically significant difference from the control (p<0.05). Data
represent an average of three independent experiments ± the standard error of the
mean.

Because both centrosome separation pathways appear to be downregulated
after Cr(VI) exposure, we hypothesized that premature centrosome separation after
Cr(VI) treatment might be due to a failure of the G1-G2 tether to form. If this were the
case, centrosome separation would still be possible even without Nek2 and Eg5 activity
and localization. To determine if Cr(VI) affects the formation of the G1-G2 tether we
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analyzed centrosomal localization of C-Nap1 and Rootletin, two key linker proteins.
Rootletin forms fiber-like structures that connect both centrosomes, while C-Nap1 serves
as a docking site for Rootletin. Even though other proteins also form fibers and provide
alternative docking sites, depletion of C-Nap1 and Rootletin alone can cause
centrosome separation because they serve as the structural basis for the rest of the
linker (Mayor et al., 2000; Bahe et al., 2005).
Figure 3.34A shows representative images of an interphase cell with C-Nap1 and
Rootletin localization to centrosomes. Chronic exposure to Cr(VI) did not affect C-Nap1
localization to centrosomes and we did not find any control or treated cell without CNap1 at centrosomes (Figure 3.34B). As for Rootletin, there seems to be a slight
increase in its centrosomal localization after Cr(VI) exposure (Figure 3.34B).
Approximately 90% of untreated cells have Rootletin at centrosomes, and this increases
to 92, 95 and 100% after 24h exposure to 0.1, 0.15 and 0.2 ug/cm2 zinc chromate,
respectively and to 100, 100 and 100% after 120 h exposure, respectively. We only
performed one experiment so statistical analysis on these data can not be performed.
However, the data strongly suggest that C-Nap1 and Rootletin are still present at the
centrosomes after Cr(VI) treatment.
Interestingly, cells with Cr(VI)-induced premature centrosome separation also
have C-Nap1 and Rootletin localized to centrosomes (Figure 3.34C). C-Nap1 was
localized to centrosomes in 100% of untreated and treated cells, while Rootletin
localization to centrosomes was 96, 96 and 100% after 24, 72 and 120 h exposure to 0.2
ug/cm2 zinc chromate, respectively (Figure 3.34D). In summary, the analysis of C-Nap1
and Rootletin localization to centrosomes shows that centrosome separation after Cr(VI)
exposure occurs despite the presence of C-Nap1 and Rootletin.
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Figure 3.34. C-Nap1 and Rootletin Localization at Centrosomes after Cr(VI) Exposure.
This figure shows that Cr(VI) does not affect C-Nap1 and Rootletin localization to
centrosomes. A) Representative images of an nterphase cell (DNA in blue) showing CNap1 (red) and Rootletin (green) localization to centrosomes. B) Percent of interphase
cells with C-Nap1 and Rootletin localization to centrosomes after Cr(VI) exposure. C)
Representative images of an interphase cell (DNA in blue) with separated centrosomes
and C-Nap1 (red) and Rootletin (green) localization to centrosomes. D) Percent of
interphase cells with separated centrosomes with C-Nap1 and Rootletin localization to
centrosomes after Cr(VI) exposure. Data represent one experiment.
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Figure 3.34. Continued.
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3.4.4. Part 3 Summary
In Part 3 we demonstrate that chronic exposure to particulate Cr(VI) affects
multiple proteins involved in the regulation of the centriole linkers. Specifically, Cr(VI)
increases the levels of active Plk1 in interphase cells. We also found that after Cr(VI)
exposure cells securin as well as inactive separase levels are decreased, while active
separase levels are increased. These changes are consistent with the premature
centriole disengagement observed in interphase cells after Cr(VI) treatment.
In contrast, we show that Nek2 and Eg5 protein levels and their centrosome and
microtubule localization, respectively, are decreased after chronic exposure to Cr(VI).
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We also show that the localization of key G1-G2 tether proteins is not affected by Cr(VI).
These results are not consistent with the premature centrosome separation caused by
Cr(VI).

3.5. Overall Summary of Results
Part 1 demonstrates that centrosome amplification induced by Cr(VI) is a
permanent phenotype and that it correlates with permanent numerical chromosome
instability. Part 2 shows that exposure to Cr(VI) causes premature centriole
disengagement and premature centriole separation in interphase cells. Part 3 shows that
Cr(VI) activates the proteins that regulate centriole disengagement. It also suggests that
centrosome separation after Cr(VI) exposure may be mediated through novel
mechanisms. In summary, the data show that centrosome amplification after Cr(VI)
exposure is permanent and that Cr(VI) affects the protein linkers that regulate the
centrosome, providing a feasible mechanism for centrosome amplification.
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CHAPTER 4
DISCUSSSION

4.1. Overview
In general, lung tumors are characterized by very complex karyotypes with
numerical chromosome instability (Balsara and Testa., 2002; Haruki et al., 2001,
Masuda et al., 2002). Multiple cellular mechanisms contribute to changes in
chromosome numbers. This work focuses on one of those mechanisms: centrosome
amplification. Centrosome amplification is prevalent in solid tumors, including those of
the lung (Pihan et al., 1998). Centrosomes are key players because one of their main
roles is to form the bipolar spindle that evenly divides the genetic material during mitosis.
Therefore, supernumerary centrosomes (i.e. centrosome amplification) can lead to
numerical chromosome instability.
Cr(VI) is a metal widely used in industry and a common environmental pollutant.
It is also a well-established human lung carcinogen. However, its carcinogenicity
remains poorly understood. Cr(VI) induces centrosome amplification in human lung cells
as well as numerical chromosome instability (Holmes et al., 2010). But the mechanisms
underlying Cr(VI)-induced centrosome amplification are unknown. It is also unknown
whether this phenotype is transiently induced or persists after Cr(VI) exposure.
In normal cells, centrosomes duplicate once and only once per cell cycle.
Duplication is triggered by the disengagement of their underlying structures, the
centrioles. Thus, centriole disengagement is considered the licensing step for
centrosome duplication (Tsou and Stearns, 2006a; 2006b). Centrioles are kept engaged
by a group of proteins collectively referred to as the S-M linker because the linker forms
in S phase and is normally degraded during late mitosis or very early in G1 (Nigg and
Stearns, 2011). Then, after centrosomes duplicate, they are kept together by another
115

group of proteins referred to as the G1-G2 tether (Nigg and Stearns, 2011). This tether is
split at the G2/M transition and allows for centrosome separation in prophase (Mardin
and Schiebel, 2012). Moreover, Plk1 activation is involved in both centriole
disengagement and centrosome separation, suggesting common upstream regulatory
mechanisms. Overall, it appears that the linkers are involved in preventing centrosome
duplication until is the proper time to do so.
This project investigated the hypothesis that particulate Cr(VI) causes premature
disruption of these two centrosome linkers and whether centrosome amplification after
Cr(VI) exposure is a permanent phenotypic change. We demonstrate for the first time
that Cr(VI) induces premature centriole disengagement and premature centrosome
separation in interphase cells. Moreover, Cr(VI) causes Plk1 activation consistent with
the premature centriole disengagement and centrosome separation observed in
interphase. For centriole disengagement, we demonstrate the securin/separase pathway
is activated after Cr(VI) exposure. We also show the Nek2/Eg5 pathway might not be
responsible for Cr(VI)-induced premature centrosome separation. This project also
confirms centrosome amplification after Cr(VI) exposure is a permanent phenotypic
change.
In the following sections we discuss the data that show that particulate Cr(VI): 1)
causes a permanent centrosome amplification phenotype (Section 4.2), 2) induces
premature centriole disengagement through Plk1, separase and securin deregulation
(Section 4.3) and 3) promotes premature centrosome separation independent of Nek2
and Eg5 (Section 4.4).
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4.2. Part 1: Particulate Cr(VI) Causes Permanent Centrosome Amplification
Centrosome amplification is considered a deleterious phenotype because
extremely uneven cell divisions likely lead to unviable daughter cells. However, tumors
harbor cells with centrosome amplification and their presence correlates with numerical
chromosome instability and tumor progression (Pihan et al., 2001; Lingle et al., 2002;
Pihan et al., 2003). This outcome suggests that cells with amplified centrosomes do
survive and play a role in carcinogenesis. A longstanding debate regarding cells with
multiple centrosomes is whether they survive or not because it is expected that cells that
undergo multipolar division will have such an abnormal genetic content that they will be
unviable. Consequently, we investigated whether centrosome amplification is a
permanent phenotypic change after Cr(VI) exposure.
In order to address this, we analyzed centrosome amplification in a set of clonal
cell lines that were developed after one, two or three exposures to Cr(VI) (i.e.: named
first, second or third generation, respectively). Each cell line derives from a single cell
that survived and divided after Cr(VI) exposure. Hence, the phenotypes that are
observed in each cell line can be considered heritable and permanent. Cells with
amplified centrosomes appeared as early as the first generation and remained present
throughout the second and third generations. The highest percent of cells with
centrosome amplification was observed in clone T5 with 22% of cells with centrosome
amplification. This percent is consistent with the highest values found in multiple cancer
cell lines (Nigg, 2002).
It is curious that the 3rd generation of clones had a lower percent of clones with
centrosome amplification than the first two. This outcome is most likely due to increased
cell death in the 3rd generation. However, the decrease may also indicate that over time
the phenotype is lost as a result of the clonal selection and expansion. Chiba et al.
(2000) used cell lines from single p53-deficient mouse epithelial cells to study the fate of
117

the centrosome amplification phenotype. As expected, these cell lines have centrosome
amplification due to p53 deficiency as well as abnormal chromosome numbers.
Interestingly, these cell lines retained the centrosome amplification phenotype
approximately until passage 30, but at later passages the surviving cells had normal
number of centrosomes. In addition, chromosome numbers were abnormal but highly
heterogeneous in the earlier passages (i.e.: 30 passages) but at later passages
surviving cells had abnormal but stable number of chromosomes. This raises the
possibility that centrosome amplification might be selected out as chromate-treated
clones are expanded. However, the consequences of centrosome amplification, such as
numerical changes in chromosomes, would persist.
In order to further understand the presence of centrosome amplification and
numerical CIN, we analyzed clonal pedigrees. Clones from different generations are
related to each other, hence family pedigrees allow us to analyze how centrosome
amplification and numerical CIN phenotypes change as clones are treated, selected and
expanded. The pedigrees show that clones with a high percentage of cells with
centrosome amplification, such as T5, have truncated pedigrees because there are not
enough surviving daughter colonies. In addition, the only surviving colonies have normal
karyotypes and do not have centrosome amplification. Lack of surviving colonies is also
observed in clones that have intermediate centrosome amplification but extremely
abnormal karyotypes such as T1-1 and T4-2. In contrast, clones with karyotypes closer
to normal and intermediate levels of centrosome amplification give rise to clones that
survive, such as T2-2 and T2-3. The surviving clones continue to have karyotypes closer
to normal and intermediate levels of centrosome amplification.
We found numerical CIN increased significantly in the second and third
generations. Moreover, this increase correlated with the increase in centrosome
amplification in the previous generation. This is consistent with centrosome amplification
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being a causative mechanism that leads to induction of numerical CIN (Lingle et al,
2002). An interesting observation is that the majority of cell lines that have numerical
CIN in the form of a near-tetraploid or tetraploid complement (i.e.: 92, XXYY) did not
show centrosome amplification. Given that tetraploidy most likely derives from mitotic
failure or lack of cytokinesis, it is expected that these cells would also acquire extra
centrosomes. Thus, the observation that these clones do not show centrosome
amplification is intriguing. One explanation, albeit untested, is that these cells lose
centrosomes by actively extruding them, a phenomenon previously described in oocytes
(Sutovsky and Schatten, 1999). However, it is currently unknown if centrosome extrusion
can happen in somatic cells or cells that have undergone transformation.
The pedigree analysis shows cell lines with low to moderate levels of centrosome
amplification and numerical CIN survive even in response to a new Cr(VI) treatment.
Supporting this observation, Weaver et al. (2007) used CENP-E+/- mice to show that
numerical CIN can act both oncogenically as well as a tumor suppressor depending on
the level of genomic instability that is induced.
Our data show cells with centrosome amplification survive and duplicate and that
cell lines can survive with a certain percent of the population with centrosome
amplification. This outcome is consistent with what has been observed in multiple cancer
cell lines (Nigg, 2002). In summary, the analysis of centrosome amplification in clonal
cell lines developed after Cr(VI) exposure confirms this phenotype is stable and
persistent and that it correlates with the presence of numerical CIN, which is also
persistent. In addition, these cell lines can also become useful tools for addressing
pending questions regarding centrosome biology.
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4.3. Part 2: Particulate Cr(VI) Induces Premature Centriole Disengagement
Through Deregulation of Plk1, Separase, and Securin
After confirming that centrosome amplification after Cr(VI) exposure is a
permanent phenotype, we sought to investigate the underlying mechanisms that
contribute to its development. Centriole disengagement is a key step in the centrosome
cycle because it is the licensing step for centriole duplication (Tsou and Stearns, 2006a;
2006b). If centrioles disengage at other points of the cell cycle, the result is centrosome
amplification because each disengaged centriole can become a centrosome. Moreover,
centriole disengagement

triggers centriole duplication

which further

increases

centrosome numbers.
Centriole disengagement normally occurs at the end of mitosis (telophase) or
very early in G1 phase (Kuriyama and Borisy, 1981). We hypothesized that Cr(VI)
exposure causes premature centriole disengagement. To address this, we used
centriole markers that distinguish if centrioles from a centrosome remain engaged to
each other or not (Tsou and Stearns, 2006b). Our data show that chronic exposure to
Cr(VI) caused a time- and dose-dependent increase in centriole disengagement in S/G2
interphase cells. These results are in agreement with other studies that have shown
premature centriole disengagement in human cells after exposure to DNA damaging
agents such as radiation and doxorubucin (Saladino et al., 2009; Conroy et al., 2012;
Douthwright and Sluder, 2014). This

data suggest that

premature centriole

disengagement might be a general response to DNA damaging agents. Interestingly,
mitotic cells did not show premature centriole disengagement after Cr(VI) exposure. In
addition, centriole disengagement was not observed in telophase cells, which would be
considered a normal phase for disengagement. In contrast, about 50% of G1 cells had
disengaged centrioles suggesting that in human lung fibroblasts normal centriole
disengagement occurs in G1 phase.
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Because centriole disengagement is the licensing step for centriole duplication
(Tsou and Stearns, 2006b) an increase in the number of centrioles would also be
expected in Cr(VI)-treated cells. Centrin staining confirms that chronic exposure to Cr(VI)
induces supernumerary centrioles in both interphase and mitotic cells. Because we did
not observe centriole disengagement in mitotic cells, the mitotic cells with
supernumerary centrioles likely derive from interphase cells with premature centriole
disengagement and supernumerary centrioles that entered mitosis (Douthwright and
Sluder, 2014).
After confirming Cr(VI) induces centriole disengagement we investigated how
Cr(VI) affects the proteins involved in this phenotype. Centriole disengagement appears
to be regulated by Plk1 and the separase/securin complex (Tsou and Stearns, 2006b;
Wang et al., 2008; Nakamura et al., 2009; Tsou et al., 2009; Hatano and Sluder, 2012)
acting on the S-M linker which remains poorly defined but includes cohesin, sSgo1 as
well as components of the PCM (Sluder, 2014). We hypothesized that Cr(VI)-induced
premature centriole disengagement might be the result of Plk1 activity which promotes
separase activity through securin degradation (Waizenegger et al., 2002, Tsou et al.,
2009).
We found that after a 24 h exposure levels of active and inactive Plk1 were
similar to the control. In contrast, 72 and 120 h exposures greatly decreased the levels
of inactive Plk1 but did not affect the levels of active Plk1. This results in an increased pPlk1/Plk1 ratio and suggests that after chronic exposure to Cr(VI) the majority of Plk1 is
in its active form. In normal conditions Plk1 is activated late in G2 by Aurora Adependent phosporylation of threonine 210 (Macurek et al., 2008). However, in the
presence of DNA damage, cells with an intact DNA damage response inactivate Plk1
through dephosphorylation (Smits et al., 2000). Our data suggest that despite the
presence of Cr(VI)-induced DNA damage, cells do not dephosphorylate Plk1.
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Considering that Cr(VI) is a potent genotoxicant, it is surprising that after 72 and 120 h
exposures Cr(VI)-treated cells most of Plk1 is phosphorylated. This outcome suggests
defective Plk1 inactivation. Moreover, Plk1 activity also regulates mitotic entry and
checkpoint recovery (van Vugt et al., 2004; Macurek et al., 2008). Since Cr(VI)-treated
cells arrest at G2 (Holmes et al., 2010), failure to inactivate Plk1 could allow cells with
DNA damage (Smits et al, 2000) and centrosome defects to enter mitosis.
Only one previous study has Cr(VI) impacts on Plk1 (Chun et al., 2010). In this
study, human lung fibroblasts were treated for 24 h with soluble Cr(VI) did not show
changes in Plk1 kinase activity as measured by an in vitro kinase assay, but did observe
a decrease in Plk1 protein levels and nuclear localization. The kinase activity data is
consistent with the data showing the ratio of active vs. inactive Plk1 remains unchanged
after 24 h exposure suggesting no changes in Plk1 activity after this exposure time.
In addition, two studies have analyzed Plk1 after exposure to other metals. Chen
et al. (2011) performed western blot analysis of active Plk1 in HeLa cells arrested in
mitosis after a 24 h treatment with arsenic trioxide and showed that active Plk1 was
present and that it might be involved in maintaining the arrest. Huang et al. (2009)
observed subtle localization changes in Plk1 localization in the midbody during
cytokinesis in NIH3T3 cells exposed to titanium dioxide nanoparticles. The authors
suggested that these changes may underlie failure of cytokinesis under the same
treatment conditions. In contrast, Cr(VI) does not induce failure of cytokinesis or mitotic
arrest (Holmes et al., 2010). However, these studies suggest that Plk1 might be a
common target in metal toxicity, albeit through different mechanisms.
So how does Plk1 remain active after Cr(VI) treatment? One possibility, yet
untested, might involve Cr(VI)-induced defects in DNA damage response and repair
proteins. Several studies have shown that Plk1 inactivation upon DNA damage depends
on ATM, ATR and BRCA1 (van Vugt et al, 2001; Tsvetkov and Stern, 2005; Zou et al.,
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2013). Even though a 24h exposure to Cr(VI) induces ATM phosphorylation
(i.e.:activation), longer exposures greatly decrease the levels of phosphorylated (i.e.:
active) ATM (Qin et al., 2014). Hence, a diminished DNA damage response after Cr(VI)
treatment might be partially responsible for lack of Plk1 inactivation.
We also considered the protease separase whose activation is regulated by Plk1
(Cohen et al., 1996; Waizenegger et al., 2002; Moshe et al., 2004) and leads to centriole
disengagement (Tsou et al., 2009). Upon activation separase undergoes autocleavage
and the resulting cleaved fragments migrate differentially on gels and can be detected by
western blotting (Zou et al. 2002). We used interphase cell lysates to analyze full-length
and cleaved separase after Cr(VI) exposure. Our data shows prolonged Cr(VI) exposure
decreases full-length and inactive separase levels, while increasing its cleaved and
active products, showing separase activation in interphase cells. Since separase
activation is controlled by association with its inhibitor securin (Cohen et al., 1996) we
also analyzed securin levels. After chronic exposure to Cr(VI), securin levels dropped
significantly, which is consistent with separase activation.
Only a few studies have considered changes in securin and separase after
exposure to metals. Similar to our study, Chao et al. (2006) observed a decrease in
securin and slight increase in separase cleavage products after exposure to arsenite in
vascular endothelial cells. In contrast, McNeelly et al. (2008) have reported increased
securin protein levels after arsenite exposure in human malignant melanoma cells. The
difference in response between these studies could be attributed to different cell lines or
higher arsenite concentrations used by Chao et al. (2006). Consistent with our findings,
Prosser et al. (2012) analyzed Plk1, APC/C, separase and securin in HeLa cells
exposed to ionizing radiation. They found premature centriole disengagement during a
G2 arrest which could be blocked by overexpressing inactive Plk1 or securin or by
depleting APC or separase. The authors concluded that oscillations in APC/C activity
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during a G2 arrest lead to securin degradation, separase activation and premature
centriole disengagement.
In

summary,

chronic exposure

to

Cr(VI)

induces

premature centriole

disengagement during interphase and affects the proteins that are involved in regulating
this important step of the centrosome cycle. This data also provides novel targets for
Cr(VI) toxicity and offers mechanistic insights into Cr(VI)-induced centrosome
amplification. Moreover, the observed effects can also help explain changes in other
Cr(VI) targets other than centrosomes.

4.4. Part 3: Particulate Cr(VI) Induces Premature Centrosome Separation Likely
Independent of Nek2 and Eg5
We also considered whether Cr(VI) affects the other centrosome linker: the G1G2 tether. In a normal cell cycle, the G1-G2 tether is formed between centrioles soon
after they disengage in late mitotis/early G1, (Nigg and Stearns, 2011). Since each
centriole will soon become an individual centrosome, the G1-G2 tether maintains the two
centrosomes together and thereby ensures that they function as one microtubule
organizing center throughout interphase. Late in G2 the tether is broken to allow
centrosome separation during mitosis and bipolar spindle formation (Agircan et al.,
2014).
In addition, a recent study by Conroy et al. (2012) showed that this linker is also
involved in preventing centriole disengagement caused by ionizing radiation-induced
DNA damage. Even more interesting is that the dissolution of this linker is dependent on
Plk1 activity (Zhang et al., 2005; Mardin et al., 2011). Considering that Cr(VI) causes
premature centriole disengagement, activates Plk1 and causes DNA damage, we
hypothesized that exposure to Cr(VI) could cause premature centrosome separation in
interphase cells.
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To analyze this we measured the distance between centrosomes in interphase
cells after Cr(VI) exposure. We observed after 24 h exposure that the percent of cells
with separated centrosomes decreased compared to background levels. This decrease
after 24 h is actually considered a normal response, as cells with damaged DNA inhibit
centrosome separation as part of the overall cell cycle arrest (Zhang et al., 2005). Since
Cr(VI) causes DNA damage at later time points (Holmes et al., 2008), the decrease in
centrosome separation should persist. However, after 72 and 120 h, this percent
increased significantly showing that chronic exposure to Cr(VI) induces premature
centrosome separation in interphase.
The overall separation of centrosomes proceeds in two steps. The first step,
linker dissolution, involves the phosphorylation of the linker components C-Nap1 and
Rootletin by the Nek2A kinase causing their removal from centrosomes (Fry et al.,
1998b; Helps et al., 2000; Bahe et al., 2005). The second step, termed centrosome
separation or elongation, refers to the migration of centrosomes away from each other.
This requires microtubule forces primarily driven by the motor protein Eg5 (Blangy et al.,
1995).
To further understand the mechanism underlying Cr(VI)-induced premature
centrosome separation in interphase we focused our attention on Nek2 as this kinase is
present and active during S and G2 phases (Fry et al., 1995). Specifically, the isoform
Nek2A is involved in centrosome separation (Hames and Fry, 2002). Western blot
analysis showed that Cr(VI) exposure decreases Nek2A protein levels. Next, we
analyzed its centrosomal localization. For this, isoforms A and B cannot be distinguished
from each other. In agreement with the decrease in protein levels, we also observed a
decrease in Nek2 centrosomal localization in interphase cells. Interestingly, this
decrease did not affect G2 cells, as all G2 cells analyzed had Nek2 localization to
centrosomes. We then tried to asses levels of phosphorylated Nek2, which is the active
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form (Fry et al., 1999). Since no commercially available antibodies exist, we
immunoprecipitated Nek2 and blotted for phospho-threonine and phospho-serine.
Unfortunately, we were not able to detect good bands in the blots and hence, could not
quantify active Nek2.
Even though we could not assess active Nek2, our data shows an overall
decrease in protein levels and centrosomal localization. These trends are not consistent
with the observed increase in centrosome separation. Multiple studies have analyzed
Nek2 protein levels, centrosomal localization and kinase activity, and increased
centrosome separation is only observed when these parameters are increased (Fry et
al., 1995; Fry et al., 1998a, Hames and Fry., 2002; Faragher and Fry, 2003).
Interestingly, DNA damage has been shown to inhibit Nek2 activity as well as decrease
its protein levels (Fletcher et al., 2004; Mi et al., 2007). However, in these studies
centrosome separation was also inhibited.
Only one study has analyzed premature centrosome separation. Mardin et al.,
(2013) showed that epithelial growth factor (EGF) signaling can drive premature
centrosome separation in non-transformed as well as tumor-derived cell lines.
Premature centrosome separation was mediated by Nek2 activity and reduced the
requirement for Eg5. An interesting observation from this study is that in tumor-derived
cell lines premature centrosome separation allows for a more accurate segregation of
chromosomes and hence increases the survival of genetically unstable cells (Mardin et
al. 2013). This increase in accurate chromosome segregation is due to centrosomes
separating and being positioned at opposite poles before nuclear envelope breakdown,
which decreases the incidence of abnormal kinetochore-microtubule attachments
(Kaseda et al., 2012; Mchedlishvili et al., 2012; Silkworth et al., 2012).
Because the decreases in Nek2 protein levels and centrosomal localization
cannot explain the increase in premature centrosome separation we considered Eg5. It
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has been shown that in the absence of Nek2, Eg5 activity is enough to separate
centrosomes without the release of the linker protein Rootletin (Mardin et al., 2010).
Most likely the microtubule forces exerted by Eg5 can tear the linker apart. As with Nek2,
we measured protein levels of Eg5 and Eg5 phosphorylated at threonine 927, which
allows binding to microtubules and centrosomes (Blangy et al, 1995; Cahu et al., 2008).
In interphase cells, Cr(VI) decreased levels of both Eg5 and phospho-Eg5 and Eg5
localization to the microtubules.
The decreases in Nek2 and Eg5 do not explain the increased centrosome
separation after Cr(VI) exposure. Recently, new players have been proposed to act on
centrosomes and cause centrosome separation. These include kinetochore-generated
forces via the microtubules and motor proteins such as Kif15 and dynein (Tanenbaum
and Medema, 2010; Mchedlishvili et al., 2012; van Heesben et al., 2013). The effects of
Cr(VI) on these proteins is currently unknown.
If microtubule forces generated by other motor proteins were acting on
centrosomes, one could expect Rootletin to still be localized to separated centrosomes,
as it has been previously observed for Eg5-induced centrosome separation in cells with
deficient Nek2 (Mardin et al., 2010). Rootletin presence in separated centrosomes is
likely due to the microtubule forces acting on the linker and disrupting Rootletin, as
opposed to its complete removal when it is phosphorylated by Nek2 (Bahe et al., 2005).
To test this, and at the same time, rule out a deficiency of linker proteins at the
centrosomes, we analyzed Rootletin and C-Nap1 localization to centrosomes in
interphase cells.
The vast majority of cells had both proteins localized to centrosomes, and this
was unaffected by Cr(VI) exposure. Hence, premature centrosome separation is not
likely due to a lack of linker proteins. Next, we focused the analysis on separated
centrosomes. Interestingly, both C-Nap1 and Rootletin were also present with no
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changes after Cr(VI) exposure, indicating that the mechanism separating centrosomes
does not involve Rootletin release from the centrosomes.
The presence of Rootletin in separated centrosomes suggests a mechanism
involving microtubule forces. Even though not a focus of this dissertation, we do observe
centrosomes that lack centrioles (i.e.: acentriolar centrosomes) in cells exposed to
Cr(VI). These have been proposed to arise due to microtubule forces acting on the
pericentriolar material and fragmenting it (Maiato and Logarinho, 2014). These
microtubule forces could also act on linker proteins and cause their fragmentation as
well. Even without motor proteins, centrosomes would separate, albeit slowly, by
diffusion or through other microtubule movements.
Taken together our data show that Cr(VI) causes premature centrosome
separation in interphase cells. This increase correlates with the increase in centriole
disengagement, but whether these two phenotypes are related remains unknown. The
decreases in Nek2 and Eg5 protein and localization, and the presence of Rootletin in
separated centrosomes suggest a mechanism in which microtubule forces may be the
driving force behind Cr(VI)-induced centrosome separation. The effects of the premature
centrosome separation phenotype also remain unknown. It would be interesting to test if
this allows for increased survival in Cr(VI)-treated cells, as previously observed in HeLa
cells with premature centrosome separation (Mardin et al., 2013).
In summary, this work further shows that centrosomes and centrosomal proteins
are targets of Cr(VI) toxicity and that the effects are multiple and diverse, and highlights
the complexity of this human carcinogen.

4.5. Proposed Mechanism for Cr(VI)-Induced Centrosome Amplification
Considering our data we propose a mechanism by which Cr(VI) induces
centrosome defects that lead to centrosome amplification (Figure 4.1). When a cell is
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exposed to particulate Cr(VI) [1], the particle dissolves on the extracellular medium [2].
The chromate anion enters the cells using generic anion transporters [3] (DeFlora and
Wetterhahn, 1989) and once inside the cells is rapidly reduced to Cr(III) producing Cr(V)
and Cr(IV) species, as well as reactive oxygen intermediates [4] (De Flora and
Wetterhahn, 1989; Shi et al., 2009). The reduction of Cr(VI) induces DNA damage,
particularly DNA double strand breaks [5] (Xie et al., 2005; Xie et al., 2009) which lead to
a G2 arrest [6] (Holmes et al., 2010). In a normal scenario, the cell cycle arrest should
inhibit Plk1 via phospho-ATM (van Vugt et al., 2001) but since Cr(VI) decreases
phospho-ATM levels [7] (Qin et al., 2014) Plk1 remains active [8]. Plk1 activity triggers
securin degradation and frees separase [9], which acts on the proteins of the S-M linker
causing premature centriole disengagement in interphase [10]. This event licenses
centriole duplication and causes centrosome amplification [11] (Holmes et al., 2010).
Centrosome amplification leads to numerical CIN [12] (Holmes et al., 2006b; Holmes et
al., 2010). Centrosome amplification and numerical CIN are persistent phenotypes [13],
which can drive tumorigenesis causing neoplastic transformation [14] (Xie et al., 2007)
and ultimately, cancer. By an unknown mechanism Cr(VI) also induces premature
centrosome separation [15]. This may favor the survival of genetically unstable cells,
thus contributing to the permanence of the phenotypes involved in tumorigenesis [16].
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Figure 4.1. Proposed Mechanism for Cr(VI)-Induced Centrosome Amplification. This figure shows a proposed mechanism of how
Cr(VI) induces centrosome amplification. Particulate Cr(VI) (1) dissolves in the extracellular medium (2). The chromate anion enters
the cells using generic anion transporters (3) and once inside the cells is rapidly reduced to Cr(III) producing Cr(V) and Cr(IV)
species, as well as reactive oxygen intermediates (4). The reduction of Cr(VI) induces DNA double strand breaks (DBSs) (5) causing
a G2 arrest (6). The cell cycle arrest should inhibit Plk1 via phospho-ATM but since Cr(VI) decreases phospho-ATM levels (7 ) Plk1
remains active (8). Plk1 activity triggers securin degradation and frees separase (9) causing premature centriole disengagement
(CD) (10). This causes centrosome amplification (11) and numerical chromosome instability (12) both of which are persistent
phenotypes (13) which can drive tumorigenesis causing neoplastic transformation and ultimately, cancer (14). By an unknown
mechanism Cr(VI) also induces premature centrosome separation (CS) (15). This may favor the survival of genetically unstable cells,
thus contributing to the permanence of the phenotypes involved in tumorigenesis (16).
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4.6. Future Work
The phenotypes observed in this study have mostly been described in the
literature under conditions in which tumor cells are manipulated to become synchronous,
to arrest at certain cell cycle phases, or to express or repress proteins. Our work is the
first to show the effects of relevant doses of a chemical carcinogen and environmental
pollutant on centrosome biology in normal human cells. It also provides further
knowledge of Cr(VI) toxicity and new targets that had not been described for Cr(VI) or
other metal carcinogens. However, this study also raises new questions to pursue and
opens many future research directions.
First, there are experiments that could not be addressed in this dissertation due
to time constraints or experimental issues. One such experiment is the confirmation that
Plk1 is indeed driving the phenotypes we observe. As mentioned previously, reversal
experiments are instrumental to proving cause-effect relationships. Fortunately, Plk1 is a
widely studied target and highly specific inhibitors as well as plasmid systems allow for
its manipulation in cells. It would be of extreme interest to either inhibit Plk1 or
overexpress a kinase-dead protein and show that we can revert premature centriole
disengagement, the changes observed in separase and securin protein levels, and, most
importantly, centrosome amplification and numerical CIN after Cr(VI) exposure.
Currently, there are several clinical trials with Plk1 inhibitors. If Plk1 proves to be a driver
of numerical CIN after Cr(VI) exposure, it could become a potential target for therapy of
Cr(VI) workers with lung cancer.
Moreover, since the mechanism underlying premature centrosome separation
remains elusive, Plk1 manipulation could help find targets to study this phenotype,
provided that it was also reversed. In addition, specific kinesin inhibitors could be tested
to see if they contribute to centrosome separation and even unravel new players
involved in this important aspect of centrosome biology. Another interesting question to
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address is when centrosome separation is happening. Preliminary testing using cyclin
D1 as a marker shows that it could be as early as G1, but more in depth analyses need
to be performed.
For centriole disengagement, the timing also needs to be confirmed. Even
though our studies show that it happens in S and/or G2 cells, it would be important to
distinguish between these. This distinction would also allow assessing the involvement
of the G2 arrest in the induction of this phenotype. Since many studies show that cell
cycle arrest allows for centrosome defects, a possible way to overcome centrosomeassociated defects could be by means of overriding a cell cycle arrest and push cells
into mitosis where they are more sensitive to therapeutical approaches.
Time-lapse imaging of cells expressing GFP-centrin would provide insight into
the

timing

and

interconnectedness

of

centrosome

separation

and

centriole

disengagement, as well as answer other interesting questions. Can both phenotypes
happen in the same cell? Or are they mutually exclusive? Does centrosome separation
precede centriole disengagement? Or vice versa? When does centriole duplication begin
after centriole disengagement? Do these phenotypes slow or accelerate the time spent
in interphase or mitosis? Do Cr(VI)-treated cells cluster supernumerary centrioles and
centrosomes? The clonal cell lines would be good candidates for the time-lapse studies
because we know that in these the phenotypic changes are permanent.
Future studies should also use the clonal cell lines to test permanent changes in
protein levels and localization of key centrosome proteins that are involved in numerical
CIN, as well as other phenotypes. Also, considering the reports that suggest that
premature centrosome separation may allow for an increase in the fidelity of mitosis, it
would be interesting to analyze premature centrosome separation in the clones. Clones
with low, medium and high levels of premature centrosome separation could be further
observed using live imaging to assess time spent in mitosis and observe the incidence of
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lagging chromosomes, anaphase bridges and mitotic figures that contribute to numerical
CIN. Moreoever, it would be interesting to see the growth curves of the clones with
different degrees of premature centrosome separation to see if the phenotype provides a
proliferative advantage.
Another promising future area of research is the link between the DNA damage
response and centrosome biology. Given that Cr(VI) is such a potent genotoxicant and
causes defects in DNA repair, it would be interesting to study if a defective DNA damage
response is involved in centrosome amplification after Cr(VI) exposure. Multiple DNA
repair proteins have been shown to localize to the centrosome and cause centrosome
abnormalities, many of which (i.e.: MRN complex, ATM, Rad51, Rad51C, BRCA1) are
affected by Cr(VI). Because these proteins are downregulated by Cr(VI), it would be
interesting to study if their overexpression can revert centrosome amplification. At the
same time, multiple centrosomes could also contribute to defective DNA repair by
affecting key signaling pathways involved in the DNA damage response. To our
knowledge, this has not been explored but Cr(VI) might be a good model to use for
these studies.
In summary, the study of centrosomes has the potential to shed light on many
aspects of Cr(VI) toxicity and carcinogenesis. Because of their pivotal role in cell
division, microtubule-related functions and due to their emerging connections to the
entire cell signaling machinery, the study of centrosomes forces us to think in the totality
of mechanisms that are present in a cell. As such, they provide with new ways to
address the insult of environmental toxicants and chemical carcinogens, and will likely
prove to be epicenters for therapeutic interventions in cancer cells.
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